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It has been 42 years since the heat shock response was first reported in a 
Drosophila study [Ritossa, 1962]. The heat shock proteins (HSPs) are highly conserved 
proteins that are expressed constitutively and inducibly under stressful conditions like 
heat shock, free oxygen radicals damage, ultraviolet damage and bacterial infections. 
They can be found in a wide variety of subcellular compartments like cytosol, nucleus, 
endoplasmic reticulum and mitochondria. HSPs can be divided into several families 
including HSP100, HSP90, HSP70, HSP60, HSP40 and the small HSPs. HSPs act as 
molecular chaperones to facilitate the synthesis, folding [Hartl, 1996; Gething and 
Sambrook, 1992] and degradation of proteins [Parsell and Lindquist, 1993], to 
resolubilise proteins aggregates [Ning and Sanchez, 1995], to assist in the refolding of 
denatured proteins [Schlesinger, 1990] and the transport of proteins across intracellular 
membranes [Morimoto, 1993]. HSPs first caught the attention of immunologists when 
they were shown to play a role in antigen processing and cross-presentation [Udono et 
al., 2001; Udono and Srivastava, 1993]. Subsequently, HSPs were reported to act as 
“danger signals” to the innate immune system, in which they promote differentiation 
and up-regulation of co-stimulatory molecules in antigen presenting cells (APC) 
[Singh-Jasuja et al., 2001; Somersan et al., 2001]. Furthermore, scientists in the field of 
autoimmunity had discovered the regulatory role of HSPs in inflammation [Prakken et 
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al., 2002; Prakken et al., 1997].  
HSPs in antigen processing and cross-presentation 
Srivastava and colleagues have made an important contribution to the discovery 
of the role of HSPs in cancer immunity, particularly in the processing and 
cross-presentation of antigen [Srivastava and Amato, 2001; Srivastava et al., 1998; 
Srivastava, 1993; Srivastava and Maki, 1991]. Exogenous antigens are normally taken 
up by the antigen presenting cells through endocytic pathway and presented by MHC 
class II molecules. However, in professional APC like dendritic cells, the exogenous 
antigen can be delivered into MHC class I processing and presentation pathway, a 
phenomenon termed antigen cross presentation. They found that autologous HSP-tumor 
peptide complexes could elicit specific immune responses leading to tumor rejection 
[Basu et al., 1999; Li and Srivastava, 1993; Udono and Srivastava, 1993]. In fact, some 
studies have used the autologous tumor-derived HSP-peptide complexes as a means of 
immunotherapy [Tamura et al., 1997; Janetzki et al., 2000; Eton et al., 2000; Belli et al., 
2002]. The mechanism of HSP-peptide-induced immunity is proposed to happen in the 
following manner: HSP mediates the transfer of exogenous peptides onto the major 
histocompatibility (MHC) class I molecule of antigen presenting cells (APC), 
particularly in dendritic cells, and thus cross-priming the CD8 T cells to elicit 
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anti-tumor immunity [Blachere et al., 1997; Suto and Srivastava, 1995; Srivastava et al., 
1994]. The process is reported to be dependent on receptor-mediated endocytosis 
[Arnold-Schild et al., 1999; Singh-Jasuja et al., 2000; Castellino et al., 2000]. Indeed, 
the receptor responsible for the uptake of the HSP-peptide complex has been identified 
as CD91 (also named as α2-macroglobulin receptor or low density lipoprotein-related 
receptor) [Binder et al., 2000; Basu et al., 2001; Stebbing et al., 2003; Stebbing et al., 
2004]. The importance of CD91 in antigen presentation was recently proven using 
RNA interference technology, in which short interfering RNA for CD91 that abrogate 
its expression has led to dramatic decrease of the ability of DC to cross-present 
peptides. [Binder and Srivastava, 2004]. However, other receptors for the uptake of the 
HSP-peptide complexes such as CD40 [Becker et al., 2002] and scavenger receptor A 
[Berwin et al., 2003] have also been reported.  
Most of the reported functions of HSPs in antigen cross-presentation have 
involved the mammalian HSPs, especially gp96 and Hsp70. The bacterial Hsp70, in 
fact, have a similar role to their eukaryotic counterpart in the cross-presentation of 
chaperoned peptides [Huang et al., 2000; Cho et al., 2000; Suzue et al., 1997].  
In addition to the exogenous HSP-peptide complex, loading of the HSP-peptide 
complex directly into the cytosol could also activate a specific cytotoxic T cells (CTL) 
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response, demonstrating that HSPs exert their roles in the trafficking and processing of 
the peptide in the intracellular milieu [Binder et al., 2001]. Other studies have shown 
that HSP-antigenic peptide fusion proteins can induce antigen-specific CTL response 
similar to the events seen with the HSP-peptide complexes [Rapp and Kaufmann, 2004; 
Udono et al., 2004; Udono et al., 2001; Moroi et al., 2000; Rico et al., 2000; More et al., 
1999].  
HSPs as ‘danger signals’ 
Soon after the role of HSPs in antigen presentation has been discovered, 
emerging data suggest that they are also effective activators of the innate immune 
system, promoting the maturation of dendritic cells [Wallin et al., 2002; Srivastava, 
2002]. The concept of ‘danger signals’ was first introduced by Matzinger [Matzinger, 
1998] in comparison with the customary self-nonself paradigm of the immune system 
[Janeway, 1992]. This model asserts that the immune system is more concerned with 
things that do damage than with those that are foreign [Matzinger, 2002]. HSPs 
released during necrotic cell death were found to induce maturation and secretion of 
proinflammatory cytokines like tumor necrosis factor-α (TNF-α) in dendritic cells 
[Basu et al., 2000]. Subsequently, increasing evidence show that HSPs are potent 
activators of the innate immune system [Binder et al., 2000; Singh-Jasuja et al., 2000; 
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Kuppner et al., 2001; Somersan et al., 2001; Zheng et al., 2001; Bethke et al., 2002; 
Breloer et al., 2002; Prohaszka et al., 2002; Wang et al., 2002; Flohe et al., 2003; Wan 
et al., 2004]. The signaling is reported to be mediated through the Toll-like receptor 4 
(TLR4)-Nuclear Factor-κB (NF-κB) pathway [Ohashi et al., 2000]. Nevertheless, other 
studies demonstrate that TLR2 [Zanin-Zhorov et al., 2003], CD14 [Asea et al., 2000; 
Kol et al., 2000] or CD40 [Wang et al., 2001] may play a role in the signaling. There 
are also reports showing both TLR2 and TLR4 are involved in the HSPs signaling 
[Vabulas et al., 2002a; Vabulas et al., 2002b; Vabulas et al., 2001]. 
However, due to the striking similarity of the signaling pathway between 
lipopolysaccharide (LPS, a bacterial endotoxin) and HSPs [Akashi et al., 2003; 
Kawasaki et al., 2003; Lien et al., 2000], the concern for LPS contamination is being 
highlighted recently in assessing the role of HSP in innate immunity [Bausinger et al., 
2002a]. In fact, several studies have shown that endotoxin-free HSPs are not able to 
induce dendritic cell activation [Gao and Tsan, 2003a; Gao and Tsan, 2003b; Bausinger 
et al., 2002b].  
The regulatory role of HSPs  
  Immunization of rats with mycobacterial Hsp65 could protect them from 
adjuvant arthritis induced by heat-killed Mycobacterium tuberculosis [Anderton et al., 
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1994]. The proposed mechanism is that the immunization of Hsp65 could induce 
cross-reactive T cells against mammalian self-Hsp60 (shares 48% amino acid identity 
with mycobacterial Hsp65) [Anderton et al., 1995] that may suppress the arthritic 
inflammation through secretion of regulatory cytokines like TGF-β and IL-10 
[Detanico et al., 2004; Prakken et al., 2003; Cobelens et al., 2002; Prakken et al., 2001; 
Paul et al., 2001; Wendling et al., 2000]. In addition, HSP can suppress the production 
of interleukin-4 (IL-4) and interleukin-5 (IL-5), while concurrently increasing the 
production of IL-10 in a mouse model of allergic airway inflammation [Rha et al., 
2002]. 
Aims of the project 
  Previous findings from our laboratory show that non-immunogenic and 
aggressive tumor cell-line, 3-Lewis Lung Carcinoma (3LL) cells transfected with 
mycobacterial Hsp65 gene lost their tumorigenicity and increased their 
immunogenecity [Tan et al., 2001]. In addition, mycobacterial Hsp65 is shown to help 
in the cross-presentation of an exogenous protein by dendritic cells to CD8 T cells 
without the need for complex formation between Hsp65 and the protein [Chen et al., 
2004]. This is the first report showing that a member of the Hsp60 family can 
cross-present an exogenous protein without complex formation. In this project, we are 
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particularly interested in the immunomodulatory roles of several bacterial heat shock 
proteins, namely Burkholderia pseudomallei Hsp70, B. pseudomallei Hsp60 and 
Mycobacterium bovis Hsp65. It is fascinating to examine whether their ability to 
cross-present is comparable and to look at their immunological functions collectively. 
We try to approach the problem using different models of study. We make use of the in 
vitro cell culture system to investigate the role of the HSPs in antigen presentation and 
signaling. Furthermore, we examine the immunogenicity and regulatory properties of 
HSPs using an in vivo mouse model. In view of the issue of LPS contamination, we 
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  Previous studies from our laboratory showed that the non-immunogenic and 
Lewis Lung Carcinoma cell line (3-LLC) transfected with Mycobacterium bovis Hsp65 
gene lost its tumorigenicity and gained immunogenicity in a mouse model [Tan et al., 
2001]. However, the mechanism is not fully understood in the study. Our recent results 
showed that M. bovis Hsp65 can enhance antigen cross-presentation in dendritic cells. 
In this study, ovalbumin incubated with Hsp65 was efficiently cross-presented on the 
dendritic cell-line, JAWS II, leading to the activation of naïve CD8 T cells, B3Z. 
Nevertheless, the direct activation of DC by Hsp65 was not documented. TNF-α 
secretion induced by Hsp65 was not conclusive, as the effect was abrogated in the 
presence of polymyxin B, an LPS inhibitor [Chen et al., 2004].  
In this project, we examine the immunomodulatory roles of two other heat 
shock proteins, Hsp70 and Hsp60, cloned from Burkholderia pseudomallei, the 
causative agent of melioidosis, in comparison with M. bovis Hsp65 (sharing 61 % 
similarity with B. pseudomallei Hsp60 at the amino acid level). Members from the 
Hsp70 family have been reported to participate in antigen-cross presentation [MacAry 
et al., 2004; Tobian et al., 2004; Castellino et al., 2000; Udono et al., 1993]. However, 
very little is known about the ability of the Hsp60 family members to mediate antigen 
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cross presentation except for a report using Hsp65-fusion protein [Cho et al., 2000]. 
Furthermore, we are the first to show cross presentation of whole proteins without the 
need of complexing or fusing to HSPs [Chen et al., 2004]. It is thus interesting to 
investigate both Hsp60 and Hsp65 for their ability to enhance antigen 
cross-presentation. In addition, we also examine whether these HSPs could directly 
stimulate dendritic cells, as measured by the secretion of proinflammatory cytokines 













MATERIALS AND METHODS 
Cell lines 
JAWSII (ATCC, Manassas, VA) is an immature murine dendritic cell line of C57/BL6 
origin (H-2b haplotype). The cells were cultured in complete RPMI 1640 medium 
(Sigma, St. Louis, MO) supplemented with 10 % heat-inactivated foetal calf serum 
(Gibco BRL, Grand Island, NY), 2 mg/mL L-glutamine (Sigma), 100 U/mL penicillin 
and 100 µg/mL streptomycin (Sigma) and 5 ng/mL of granulocyte macrophage-colony 
stimulating factors (GM-CSF, Gibco BRL). DC2.4 (a kind gift from Dr Wong Siew 
Heng) is a murine dendritic cell line of C57/BL6 origin (H-2b haplotype). The cells 
were cultured in complete DMEM medium (Sigma) supplemented with 10 % 
heat-inactivated foetal calf serum, 2 mg/mL L-glutamine, 100 U/mL penicillin and 100 
µg/mL streptomycin. B3Z is a mouse CD8 T cell hybridoma, which specifically 
recognizes a chicken ovalbumin epitope, SIINFEKL in the context of H-2b (a gift from 
Dr Ronald Germain, NIH) The cells were cultured in complete RPMI 1046 medium 
supplemented with 10 % heat-inactivated foetal calf serum, 2 mg/mL L-glutamine and 
100 U/mL penicillin and 100 µg/mL streptomycin. All the cells were cultured and 
maintained in a 5 % CO2 incubator at 37 °C. 
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Generation of bone marrow-derived dendritic cells (BMDC) 
Bone marrow cells were obtained and cultured according to the protocol of Lutz et al. 
Briefly, femurs and tibiae of female C57/BL6 mice were removed from the surrounding 
muscle tissue using sterile surgical tools. The intact bones were left in 70 % ethanol for 
3 min and washed with PBS. Both ends of the bones were then cut with scissors and the 
marrow was flushed with complete R10 medium (RPMI-1640 supplemented with 10 % 
FBS, 2 mM L-glutamine, 50 µM 3-mercaptoethanol, 100 U/mL penicillin and 100 
µg/mL streptomycin) using a syringe with a 0.45 mm diameter needle. The suspension 
was then centrifuged at 2,100 rpm for 5 min and washed once with PBS. The bone 
marrow cells were seeded at 5x 106 cells per 100 mm dish in 10 mL R10 medium 
containing 20 ng/mL GM-CSF. At day 3 of culture, another 10 mL of R10 medium 
containing 20 ng/mL GM-CSF was added to the culture dish. At days 6 and 8, half of 
the culture supernatant was collected and centrifuged. The cell pellet was resuspended 
in 10 mL fresh R10 medium containing 20 ng/mL GM-CSF and replated into the old 
culture dish. The cells were used for assays after 10 days of culture. 
Purification of heat shock proteins under native conditions 
The M15 E. coli clones encoding Mycobacterium bovis Hsp65, Burkholderia 
pseudomallei Hsp60 and Hsp70 were streaked on LB-agar plate containing 100 µg/mL 
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of ampicillin and 25 µg/mL of kanamycin and incubated at 37 °C overnight. Resistant 
clones were picked up and inoculated with 20 mL of LB medium overnight at 37 °C 
with constant shaking at 200 rpm. The bacterial culture was scaled up to 1 L and further 
incubated at 37 °C. After reaching 0.6 at OD600, Isopropyl-β-D-thiogalactopyranoside 
(IPTG) was added to a final concentration of 1 mM. 5 h after the induction, bacterial 
cells were pelleted down by centrifugation at 4, 000 x g for 20 min at 4 °C. Cell pellet 
was lysed in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) 
by sonication (30 s pulse on, 15 s pulse off, total process time of 10 min) on ice. The 
lysate was spun at 10, 000 x g for 20 min at 4 °C and the supernatant was harvested. 
The supernatant was then equilibrated with the Ni-NTA bead (QIAGEN, Hilden, 
Germany) overnight at 4 °C. The affinity column was packed and first washed with 
wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) containing 
0.5 % (w/v) deoxycholate and a subsequent wash without the deoxycholate. The 
proteins were eluted after two washing steps with the elution buffer (50 mM NaH2PO4, 
300 mM NaCl, 250 mM imidazole, pH 8.0). After elution, the proteins were exchanged 
into phosphate buffered saline (PBS) by ultrafiltration using Vivaspin 2 (Vivascience, 
Hannover, Germany). The concentration of the proteins were determined using 
Bradford Assay (BioRad, Hercules, CA) according to the manufacturer’s instruction 
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and absorbance was read at 595 nm using spectrophotometer (Beckman, Fullerton, CA). 
All proteins were filtered through 0.22 µm membrane filter before use. 
SDS-PAGE and Coomassie Blue staining 
The proteins were boiled in reducing sample buffer and resolved by 4 % stacking/ 8 % 
resolving sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) at 
120 V. The proteins were then stained with Coomassie Blue for identification. 
Synthetic Peptides 
Ovalbumin 8-residue peptide (SIINFEKL) and 18-residue peptide 
(EQLESIINFEKLLVLLKK) were synthesized by GL Biochem (Shanghai) to the purity 
of 81 % and 75.6 %, respectively. 
In vitro antigen presentation assay and peptide pulsing experiment 
DC2.4 or BMDC cells were seeded at 5x 104 cells per well in 96-well tissue culture 
plate (Nunc, Roskilde, Denmark). Ovalbumin (Sigma), ovalbumin SL8 peptide (GL 
Biochem, Shanghai), ovalbumin EK18 peptide (GL Biochem, Shanghai), Hsp70, 
Hsp60, Hsp65, lactoferrin (Sigma), or polymyxin B (Sigma) were added into the wells 
at appropriate final concentrations. The cells were incubated for 16 h (8 h for the 
peptide pulsing experiment) at 37 °C before B3Z cells (5x 105 cells per well) was added 
and made up to the final of 200 µL assay volume. After 24 h of culture (16 h for 
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peptide pulsing experiment), the supernatant was collected and assayed for IL-2 using 
enzyme-linked immunosorbent assay (ELISA) kit (BD PharMingen, San Diego, CA) 
according to the manufacturer’s protocol. The optical density was measured at 450 nm 
with correction at 570 nm using the Spectra Max 190 microplate reader (Molecular 
Device, Sunnyvale, CA). 
Flow cytometry analysis of CD54 expression 
DC2.4 cells were seeded at 5x 105 cell/well in a 24-well tissue culture plate. Hsp70, 
Hsp60, Hsp65, lactoferrin, polymyxin B or LPS were added into the wells at 
appropriate final concentrations. After 24 h of stimulation, the cells were washed with 
PBS and incubated with anti-CD54-FITC antibody for 30 min in dark at 4 °C. 
Fluorescence was measured using a FACScan flow cytometer (Becton Dickinson, San 
Jose, CA). 
Measurement of cytosolic calcium 
Cytosolic calcium was measured using the fluorescent calcium indicator, Fura-2-AM 
(Molecular Probes, Eugene, OR) according to the manufacturer’s instruction. Briefly, 
DC2.4 cells were pre-incubated with 1 µM Fura-2-AM for 30 min in dark. The cells 
were then washed with PBS and incubated with Hsp70, Hsp60, Hsp65, lactoferrin or 
polymyxin B at appropriate final concentrations. After 1 h of incubation, fluorescence 
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was measured using the Spectra Max Gemini microplate reader at excitation 
wavelengths of 340 nm (calcium-bound) and 380 nm (without calcium binding), and 
emission wavelength of 510 nm. Change in cytosolic calcium was indicated by the 
change of 340/380 nm excitation ratio. 
In vitro stimulation assay 
JAWS II were seeded at 5x 104 cells per well in 96-well tissue culture plate. Hsp70, 
Hsp60, Hsp65, lactoferrin, or polymyxin B were added into the wells at appropriate 
final concentrations. GM-CSF was added to a final concentration of 20 ng/mL. The 
cells were incubated for 16 h at 37 °C. The supernatants were harvested and assayed for 
TNF-α and IL-18 using ELISA kits (TNF-α ELISA kit, Bender MedSystems, Vienna, 
Austria; IL-18 ELISA kit, BD PharMingen) according to the manufacturers’ protocols. 
The optical density was measured at 450 nm with correction at 570 nm using the 
Spectra Max 190 microplate reader. 
Toll-like receptor 4 (TLR4) activation assay 
TLR4 activation assay was performed according to the protocol reported by Zhang et. 
al. Briefly, Human embryonic kidney (HEK) 293T cells were seeded in 24-well tissue 
culture plate one day before transfection. The cells were then transfected with 
expression vectors for human TLR4, MD2 and CD14, each at 100 ng/well using 
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Gene-PORTER 2 (Gene Therapy Systems, San Diego, CA) according to the 
manufacturer’s instruction. The cells were cotransfected with the p5X NF-kB-Luc 
reporter plasmid (Stratagene, La Jolla, CA) and the pRL-CMV luciferase plasmid 
(Promega, Madison, WI), each at 100 ng/mL. After 24 h, the transfected cells were 
stimulated with 50-100 µg/mL recombinant heat shock proteins in the presence or 
absence of polymyxin B for another 16 h. The NF-κB-Luciferase expression was 
determined using the Dual Luciferase Reporter Assay (DLR Assay, Promega) according 












Purification of recombinant heat shock proteins under native condition 
M. bovis Hsp65, B. pseudomallei Hsp70 and Hsp60 were expressed and purified from 
E. coli cells that were transformed to express the respective heat shock proteins (Fig 
2-1). To eliminate bacterial lipopolysaccharides (LPS), the recombinant proteins were 
washed extensively before elution with wash buffer containing deoxycholate, a potent 
LPS binder. 
B. pseudomallei Hsp60 and Hsp70 enhance cross-presentation of exogenous 
ovalbumin on DC2.4 to T cell hybridoma, B3Z. 
Previous results from our laboratory showed that Mycobacterium bovis Hsp65 
enhanced antigen cross-presentation in dendritic cells [Chen et al., 2004]. To 
investigate whether Burkholderia pseudomallei Hsp70 and Hsp60 have similar effect, 
we performed the antigen presentation assay on these two proteins in comparison to M. 
bovis Hsp65. Initially, we intended to use the JAWSII cells as antigen presentation cells. 
However, we have later used DC2.4 cells, which can be easily cultured without the 
requirement for GM-CSF. As shown in Fig 2-2, B. pseudomallei Hsp70 and Hsp60 
were able to enhance cross-presentation of ovalbumin (OVA) by DC2.4 to the CD8 T 
cell hybridoma B3Z, as determined by the increased IL-2 production. In the presence of 
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the heat shock proteins, B3Z (specific for the SIINFEKL OVA peptide presented by Kb) 
was more effectively stimulated by DC2.4 cells to secrete IL-2 as compared to DC2.4 
cells pulsed with OVA in the absence of HSP or in the presence of a control protein, 
lactoferrin. The competence of the heat shock proteins (HSPs) to promote antigen 
cross-presentation was unaffected in the presence of polymyxin B, an antibiotic that 
binds and inhibits LPS, thus excluding the possibility of LPS interference (Fig 2-3). 
B. pseudomallei Hsp60 and Hsp70 may enhance antigen cross-presentation in 
BMDC. 
To examine whether Hsp70 and Hsp60 could also promote antigen cross-presentation 
to B3Z by primary DC, we have repeated the experiments using bone marrow-derived 
dendritic cells (BMDC) as antigen presenting cells (APC). Similar results have been 
obtained for both antigen presentation assays without (Fig 2-4) or with (Fig 2-5) PMB. 
However, due to the low levels of IL-2 secreted, the data is inconclusive. 
The role of B. pseudomallei Hsp70 and Hsp60 in the presentation of the short Ova 
peptide SIINFEKL. 
To investigate whether Hsp70, Hsp60 and Hsp65 are involved in the presentation of 
short ovalbumin peptides consisting of the epitope, SIINFEKL, we pulsed the exact 
8-residue Ova SIINFEKL peptide (SL8) and the extended 18-residue peptide (EK18) 
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onto DC2.4 cells in the presence or absence of HSPs. As expected, pulsing of the SL8 
peptide resulted in overwhelming activation of B3Z regardless of the presence of HSPs 
(Fig 2-6). To our surprise, the presentation of the extended peptide (EK18) by DC2.4 
was as efficient as with SL8 and is independent of HSPs (Fig 2-7). These experiments 
have been repeated in the presence of PMB and similar results were obtained (data not 
shown).  
B. pseudomallei Hsp70 and Hsp60 are not able to up-regulate CD54 expression or 
induce calcium influx in dendritic cells. 
To determine whether Hsp70, Hsp60 and Hsp65 promote antigen cross-presentation 
through up-regulation of adhesion molecule expression and calcium influx in dendritic 
cells, we have examined the expression of CD54 (ICAM-1), an activation marker for 
dendritic cells and calcium influx in the DC2.4 upon Hsp70, Hsp60 and Hsp65 
treatments. As shown in Fig 2-8, there were no increase in the expression of CD54 nor 
calcium influx (Fig 2-9) upon treatments of Hsp70, Hsp60 and Hsp65. 
B. pseudomallei Hsp60 and Hsp70 are not able to stimulate dendritic cells to secrete 
TNF-α in the presence of LPS inhibitor. 
There had been controversy over whether bacterial and mammalian HSP60 and Hsp70 
could induce activation of DCs or monocytes as judged by the production of 
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proinflammatory cytokines. Previous findings from our laboratory [Chen et al., 2004] 
showed that the ability of M. bovis Hsp65 to induce TNF-α production was a result of 
contaminating LPS. To investigate whether B. pseudomallei Hsp60 and 70 could induce 
TNF-α production in dendritic cells, we incubated the murine dendritic cell-line 
JAWSII, with respective concentrations of recombinant Hsp70 and Hsp60 in the 
presence or absence of the LPS inhibitor, polymyxin B. Indeed, our results strongly 
support the previous findings that HSP-induced TNF-α secretion in dendritic cells was 
a consequence of contaminating LPS (Fig 2-10). 
B. pseudomallei Hsp70 and Hsp60 are not able to activate TLR4 in the presence of 
LPS inhibitor. 
Some studies had implicated the involvement of TLR4 in HSP-induced DC activation. 
However, our previous study with Hsp65 showed that the activation of TLR4 is due to 
LPS contamination (Chen et al., 2004). To further confirm the result, we investigated 
the role of B. pseudomallei Hsp70 and Hsp60 in Toll-like receptor 4 (TLR4) activation 
and subsequent NF-κB transcription, the event upstream of TNF-α production. Again, 
we showed that the activation of TLR4 by Hsp70 and Hsp60 was completely abrogated 
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Fig 2-1: Purification of recombinant (A) B. pseudomallei Hsp70, (B) Hsp60 and (C) 
M. bovis Hsp65 under native condition. 
Recombinant heat shock proteins were purified using Ni-NTA column with appropriate 
imidazole concentrations in the wash and elution steps. Proteins were visualized by 

























































































































































Fig 2-2: Enhanced ovalbumin cross-presentation by (A) Hsp70 (B) Hsp60 and (C) 
Hsp65.  
DC2.4 cells were cultured overnight in the absence of OVA (No), or in the presence of 
50 µg/mL OVA (ova), 50 µg/mL of OVA plus 5-200 µg/mL of respective heat shock 
proteins (Hsp/ova), 50 µg/mL of OVA plus 100 µg/mL of lactorferrin (Lacto/ova) in 
triplicates (some data were obtained in duplicates). IL-2 accumulation in the 
supernatant was measured 24 h after adding B3Z cells as an indicator of T cell 
activation. The results are expressed as mean ± SD of triplicates (results obtained in 

























































































































































Fig 2-3: (A) Hsp70, (B) Hsp60 and (C) Hsp65-mediated ovalbumin cross- 
presentation is not affected by polymyxin B (PMB), the LPS inhibitor.  
DC2.4 cells were cultured overnight in the absence of OVA (No), or in the presence of 
50 µg/mL OVA (ova), 50 µg/mL of OVA plus 5-200 µg/mL of respective heat shock 
proteins and 20 µg/mL PMB(Hsp/ova) , 50 µg/mL of OVA and 100 µg/mL of 
lactorferrin (Lacto/ova) in triplicates (some data were obtained in duplicates). IL-2 
accumulation in the supernatant was measured 24 h after adding B3Z cells as an 
indicator of T cell activation. The results are expressed as mean ± SD of triplicates 
(results obtained in duplicates are expressed as mean value only). The data is 












































































































Fig 2-4: Enhanced antigen cross-presentation by (A) Hsp70 (B) Hsp60 and (C) 
Hsp65 in BMDC. 
BMDC were cultured overnight in the presence of 50 µg/mL OVA (ova), 50 µg/mL of 
OVA plus 10-200 µg/mL of respective heat shock proteins (Hsp/ova), 50 µg/mL of 
OVA and 200 µg/mL of lactorferrin (Lacto/ova) in duplicates. IL-2 accumulation in the 
supernatant was measured 24 h after adding B3Z cells as an indicator of T cell 











































































































Fig 2-5: (A) Hsp70, (B) Hsp60 and (C) Hsp65-mediated antigen cross- presentation 
in BMDC is not affected by PMB. 
BMDC were cultured overnight in the presence of 50 µg/mL OVA (ova), 50 µg/mL of 
OVA plus 10-200 µg/mL of respective heat shock proteins and 20 µg/mL PMB 
(Hsp/ova), 50 µg/mL of OVA and 200 µg/mL of lactorferrin (Lacto/ova) in duplicates. 
IL-2 accumulation in the supernatant was measured 24 h after adding B3Z cells as an 













































































































































Fig 2-6: Effect of (A) Hsp70 (B) Hsp60 and (C) Hsp65 upon pulsing of SL8 onto 
DC2.4.  
DC2.4 cells were cultured for 8 h in the absence of SL8 (No), or in the presence of 50 
µg/mL SL8 (SL8), 50 µg/mL of SL8 plus 5-200 µg/mL of respective heat shock 
proteins (Hsp/SL8), 50 µg/mL of SL8 plus 100 µg/mL of lactorferrin (Lacto/ova) in 
triplicates. IL-2 accumulation in the supernatant was measured 16 h after adding of 




















































































































































Fig 2-7: Effect of (A) Hsp70 (B) Hsp60 and (C) Hsp65 upon pulsing of EK18 onto 
DC2.4.  
DC2.4 cells were cultured for 8 h in the absence of EK18 (No), or in the presence of 50 
µg/mL EK18 (EK18), 50 µg/mL of EK18 plus 5-200 µg/mL of respective heat shock 
proteins (Hsp/EK18), 50 µg/mL of EK18 plus 100 µg/mL of lactorferrin (Lacto/ova) in 
triplicates. IL-2 accumulation in the supernatant was measured 16 h after adding B3Z 




































Fig 2-8: Hsp70, Hsp60 and Hsp65 do not up-regulate the expression of CD54 on 
DC2.4 cells. 
DC2.4 cells were cultured for 24 h in the absence of modulator (A, stained ctrl), or in 
the presence of 100 µg/mL of Lactoferrin (A, Lacto), 1 µg/mL of lipopolysaccharide (B, 
LPS), 100 µg/mL of Hsp70 (C, Hsp70), 100 µg/mL of Hsp60 (D, Hsp60) or 100 µg/mL 
of Hsp65 (E, Hsp65). The stimulated cells were dislodged from the wells and stained 




















Fig 2-9: Hsp70, Hsp60 and Hsp65 do not induce calcium influx in DC2.4. 
DC2.4 cells were loaded with Fura-2-AM for 30 min before incubating with 100 
µg/mL of Lactoferrin, 100 µg/mL of Hsp70, Hsp60 or Hsp65 in the presence or 
absence of PMB in triplicates. After treatments, the cells were monitored for the change 
of 340/380 nm excitation ratios in a Spectra Max Gemini microplate reader for 1 h. The 
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Fig 2-10: (A) B. pseudomallei Hsp70 and (B) Hsp60 are not able to activate 
dendritic cells to secrete TNF-α in the presence of PMB.  
JAWSII cells were incubated with various doses of recombinant Hsp70 and Hsp60 
from 5 µg/mL to 200 µg/mL in the presence or absence of PMB in triplicates. 
Lactoferrin was used as negative control. The supernatant was harvested for TNF-α 
ELISA assay after 16 h of incubation. The results are expressed as mean ± SD of 





















Fig 2-11: B. pseudomallei Hsp70 and Hsp60-mediated activation of TLR4 is 
abolished in the presence of PMB.  
HEK 293T cells were transfected with expression vectors for human TLR4, MD2 and 
CD14. The cells were cotransfected with the p5X NF-kB-Luc reporter plasmid and the 
pRL-CMV luciferase plasmid. After 24 h, the transfected cells were stimulated with 
50-100 µg/mL of recombinant Hsp70 or Hsp60 in the presence or absence of PMB in 
triplicates for another 16 h. The NF-kB-directed firefly luciferase expression was 
normalized to the constitutive CMV-directed Renila luciferase expression and was 
expressed as relative NF-kB activation. The results are expressed as mean ± SD of 
triplicates. 





































































  Our data showed that B. pseudomallei Hsp70 and Hsp60, like their M. bovis 
Hsp65 counterpart, could assist in the cross-presentation of exogenous antigen on 
dendritic cells to the antigen-specific T cells. Presentation of chicken ovalbumin 
antigen by DC2.4 to B3Z T cells was greatly enhanced in the presence of HSPs. Hsp70 
is found to be the most potent among the HSPs in enhancing antigen cross presentation 
with its lower effective concentration (~5 µg/mL) and higher capacity in IL-2 
stimulation. We usually detect a lower level of IL-2 secretion (<20 pg/mL) upon Hsp65 
treatment. In an effort to optimize the condition, we increased the DC: B3Z ratio to 1:3 
(instead of 1:1) but still could not achieve a corresponding increase in IL-2 level (data 
not shown). Further optimization is necessary to find out the effective condition for 
Hsp65-mediated cross presentation in DC2.4 cells as our previous studies were done in 
JAWS II cells [Chen et al., 2004]. To examine if HSPs could also promote antigen cross 
presentation in primary dendritic cells, we repeated the experiment using bone 
marrow-derived dendritic cells as antigen presenting cells. The results suggest that 
Hsp70, Hsp60 and Hsp65 could also enhance antigen cross presentation in primary 
antigen presenting cells. However, the IL-2 level induced by HSPs in BMDC is low 
(<20 pg/mL). The BMDC generated in our system consists of a heterogeneous 
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population of cells that are not identical to one another in terms of cell size and 
differentiation state. They might not have equal capacity to take up, process and present 
antigen in a concerted manner. To establish a more robust system, we have to isolate 
and purify the BMDC to a near homogeneity by positively selecting the 
CD11c-expressing cell population using magnetic activated cell sorter and optimize the 
dose of HSPs, Ova and the DC to T cell ratio. 
HSPs may mediate cross-presentation of the antigen through several steps. 
Firstly, they may non-covalently associate with the target antigen and mediate their 
uptake by the antigen presenting cells through receptor-mediated endocytosis [Basu et 
al., 2001; Castellino et al., 2000]. Secondly, HSPs may also help in the intracellular 
trafficking and processing of the target antigen [Binder et al., 2001]. However, the 
exact mechanism by which HSPs promote processing of the antigen may vary between 
cell types like dendritic cells and macrophages [Tobian et al., 2004]. To further 
investigate how Hsp70, Hsp60 and Hsp65 could contribute to the presentation of the 
whole Ova protein, we utilize two short ova peptides, one of them is the exact 8-residue 
epitope SIINFEKL (SL8) and another is the extended 18-residue peptide consisting the 
SIINFEKL epitope (EK18). Under usual condition, pulsing of exact 8-residue epitope 
directly onto the MHC class I molecule of DC will activate the naïve T cells directly 
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without going through antigen processing and presentation pathway. Our data have 
confirmed that DC2.4 pulsed with SIINFEKL peptide could directly activate the B3Z 
cells to a greater extent than non-specific activation by phytohaemagglutanin (PHA, 
data not shown). Hsp70, Hsp60 and Hsp65 showed no additional enhancement on the 
activation of B3Z cells in complex with SL8 (at the concentration of 50 ug/mL). 
Presentation of extended peptides in dendritic cells is usually not as efficient as the 
exact 8-residue epitope because it needs to be processed and re-presented on MHC 
class I molecule. Our data show that the presentation of extended 18-residue (EK18) in 
DC2.4 cells is still very efficient, although less so when compared to the 8-residue 
epitope. Again, the ability of the DC2.4 cells to present the EK18 is not affected by the 
presence of Hsp70, Hsp60 and Hsp65. Our data suggest that the effect of the HSPs on 
antigen cross-presentation may be on the initial steps of uptake and processing of the 
whole proteins. As soon as the proteins are processed into short 18-residue or 8-residue 
peptides, they may no longer be subjected to modulation by HSPs. However, it is 
necessary that the peptide concentration be titrated downwards as we may be saturating 
the system. This could lead to the inability to detect enhancement mediated by HSPs. 
Indeed, subsequent work in our laboratory has showed that, for SIINFEKL peptide, 
titration down to 10 pg/mL of peptide can show enhancement by Hsp65 and Hsp70 but 
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not Hsp60, and for EK18 peptide, titration down to 25 ug/mL would show an 
enhancement by both Hsp65 and Hsp70 [Chen and Gan, unpublished data]. 
Next, to examine whether the enhanced cross-presentation of whole ovalbumin 
protein by HSPs is through the up-regulation of adhesion molecule, CD54 (also known 
as ICAM-1), we investigated the surface expression of CD54 on DC2.4 cells upon 
treatment with Hsp70, Hsp60 and Hsp65. However, there is no difference between the 
HSP-treated and untreated cells in the expression level of CD54. Clearly, HSPs may 
have promoted antigen cross-presentation in a CD54-independent pathway. 
Calcium is an important second messenger involved in numerous signaling 
pathways. Hsp70 has been reported to induce calcium flux in DCs (MacAry, 2004). It is 
not known if Hsp60 could also induce calcium flux. It is also not clear how calcium 
signaling induced by HSPs participate in antigen cross-presentation. To determine if 
our HSPs are able to induce calcium flux in DCs, we monitored the cytosolic calcium 
level upon treatment with Hsp70, Hsp60 and Hsp65 in comparison with untreated cells. 
To our surprise, we were not able to detect calcium influx from the HSP-treated cells. 
Detection of the Fura-2 fluorescence in the 96-well plate could have dampened the 
signal by the limited cell number and high background reading. Direct detection of 
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intracellular fluorescence signal by flow cytometry may serve as an alternative to 
clarify the study.  
On the other hand, our data clearly demonstrate that Hsp70, Hsp60 and Hsp65 
are not able to directly activate the DC to secrete TNF-α. Though we could see an 
increase in the production of TNF-α by DC upon treatment of HSPs, it was soon 
proven to be an effect caused by LPS contamination. Addition of polymyxin B (PMB), 
a cationic antimicrobial peptide that could bind and inhibit LPS, to the co-culture 
completely abrogated the induction of TNF-α by the HSPs. We were also unable to 
detect DC activation through the up-regulation of adhesion or costimulatory molecules 
such as CD54 and CD86 (data not shown). The TLR4-NF-κB assay has further 
confirmed the findings where activation of NF-κB by Hsp70, Hsp60 and Hsp65 
through TLR4 is abolished when PMB is added. These results prompted us to be more 
cautious in interpreting the findings obtained from HSPs purified from a bacteria 
source like E. coli. Various protocols have been developed to remove endotoxin from 
proteins [Petsch et al., 2000], however trace amount of LPS is still tricky to the assay 
systems [Bausinger et al., 2002]. Hence, in parallel to our study, we have tried to purify 
the HSPs from a non-bacteria source [Chapter IV]. Using the endotoxin-free proteins, 
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we will be able to understand the role of HSPs more specifically, particularly in ‘danger 
signaling’.  
In short, we conclude that Hsp70, Hsp60 and Hsp65 are able to enhance 
antigen-cross presentation in the dendritic cell-line, DC2.4. This process, however, is 
independent of CD54 expression as well as LPS contamination and may involve the 










EVALUATION OF IMMUNOGENICITY AND ADJUVANCITY OF 
BURKHOLDERIA PSEUDOMALLEI HSP70 AND 











  Intranasal immunization of microbial HSPs together with ovalbumin was shown 
to suppress airway inflammation and airway hyperresponsiveness in an allergic mouse 
model [Rha et al., 2002]. In this model, repeated airway challenge with ovalbumin was 
found to result in a Th2-type inflammatory response in which increased IL-4 expression 
in bronchoalveolar lavage fluid had been associated with increased IgG1 expression 
and airway hyperresponsiveness. However, if HSP was administered prior to ovalbumin 
sensitization and challenge, there was a decrease in IL-4 production while IL-10 
production was increased in the bronchoalveolar lavage fluid. IL-10 is a regulatory 
cytokine that can inhibit antigen presentation and pro-inflammatory cytokine secretion. 
It is mainly produced by CD4 T cell and in low amounts by CD8 T cell. In fact, there 
are several studies on experimental arthritis showing that immunization with HSP could 
generate regulatory, HSP-specific T cells that produce IL-10 [Detanico et al., 2004; 
Praken et al., 2002]. These findings seem to be contradicting the role of HSPs discussed 
in Chapter II in which they are found to enhance antigen cross presentation. In view of 
this, we hypothesized that B. pseudomallei Hsp70, Hsp60 and M. bovis Hsp65 could 
serve as immunomodulator that influence the outcome of intranasal immunization. We 
tested the effects of these HSPs on local and systemic cytokine production in an 
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intranasal immunization model. In addition, we also sought to understand the systemic 
and mucosal antibody response of the mice to HSPs in intranasal immunization. The 
work on B. pseudomallei Hsp60 immunization was largely conducted by another 
















MATERIALS AND METHODS 
Protein preparations 
B. pseudomallei Hsp70 and M. bovis Hsp65 were purified according to the protocols 
described in previous section. Ovalbumin protein was purchased from Sigma and 
dissolved in PBS before use. 
Mice 
6 to 8 weeks old C57/BL6 female mice were purchased from the Laboratory Animals 
Centre, Sembawang, Singapore and kept in the Animal Holding Unit of National 
University of Singapore. They were housed in cages with bedding of wood shavings 
and were fed on commercial pellets (Glenforrest Stock Feeders) and potable water ad 
libitum. All experimental procedures on animals were approved by the Animal Ethics 
Research Committee of the Faculty of Medicine, NUS. 
Intranasal immunization 
Heat shock proteins, ovalbumin and flagellin were all diluted with PBS to proper final 
concentrations. Mice were lightly anaesthetized with a combination of hypnorm and 
midazolam (CRC liquid) intraperitoneally before immunization. The protein solutions 
(20 µg in final volume of 10 to 20 µL) and PBS (control) were injected into the nostrils 
of each mouse using sterile pipette tips. The immunization schemes were depicted as 
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follows:  




Blood and nasal wash collections 
Mice were bled at day 28 and 35. The collected blood was left overnight at 4 °C to 
allow for the coagulation of red blood cells. The serum was then separated from the 
blood clot and centrifuged at 2, 700x g for 10 min at 4 °C to remove cell debris. The 
clarified serum was kept at –20 °C before analysis. Nasal wash was collected at day 35 
after the mice were euthanized. Briefly, the lower jaws of the mice were removed and 
pipette tips filled with ice-cold 1x PBS was inserted into the lower conduit of the mice 
trachea. 1x PBS was discharged to flush through the nasal cavity and the nasal wash 
was collected at the openings of two nostrils. The nasal wash was then separated from 
the tissue debris by centrifugation at 2, 700x g for 10 min at 4 °C. The clarified nasal 
wash samples were kept at –20 °C prior to analysis. 
Detection of serum and nasal wash antibodies 
M. bovis Hsp65, B. pseudomallei Hsp70 and B. pseudomallei flagellin recombinant 
Day 0 Day 14 Day 28 Day 35 
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proteins were coated on the 96-well immunosorbent plates (Nunc) at 2.5 µg/mL 
overnight at 4 °C. The recombinant proteins-coated plates were washed for 4 times 
with 0.05 % PBS-Tween 20 (PBS-T) and blocked with 0.5 % bovine serum albumin 
(Sigma) for 1 h at room temperature with shaking. After blocking, the plates were 
washed for 4 times with PBS-T . Serum samples were diluted 10x before adding to the 
protein-coated wells. Samples from nasal wash were added undiluted into the well. The 
plates were then incubated for 2 h at room temperature with shaking. The plates were 
washed for 4 times before further incubation with secondary antibody for 1 h at room 
temperature with shaking. Secondary antibody for the detection of total IgG was 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1:5,000 dilution, 
Sigma); for IgG1 was HRP-conjugated rat anti-mouse IgG1 (1:1,000 dilution, BD 
Bioscience); for IgG2a was HRP-conjugated rat anti-mouse IgG2a (1:1,000 dilution, BD 
Bioscience); for IgA was HRP-conjugated goat anti-mouse IgA (1:1,000 dilution, 
Sigma). After incubation, the plates were washed for 6 times and incubated with the 
TMB Substrate Reagent (1:1 mixing of Substrate Reagent A and Substrate Reagent B, 
BD PharMingen) for 30 min at room temperature in dark. The enzymatic reaction was 
stopped by adding of 2 N H2SO4. The optical density was measured at wavelength of 
450 nm with wavelength correction at 570 nm using Spectra Max 190 microplate 
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reader (Molecular Devices). 
Spleen and lymph nodes cells preparation 
The spleen and draining cervical lymph nodes were isolated and pooled from the 
immunized mice using sterile surgical scissors and forceps at day 35 after the mice 
were euthanized. The excised spleen was placed in a sterile 60 mm-diameter petri dish 
in 3 mL of ice-cold complete RPMI 1640 medium. The spleen was meshed up with the 
plunger of syringe. Cell clumps were dispersed by passing the splenocyte solution 
through an 18 G needle for a few times. The splenocyte suspension was then filtered 
through a 40 µm-mesh membrane and centrifuged for 10 min at 4 °C. Red blood cells 
was removed by adding of sterile water for few seconds and the subsequent adding of 
10x PBS to final of 1x PBS. The cells were then washed twice with 1x PBS before 
plating. The isolated lymph nodes were treated with collagenase mix (1 mg/mL 
collagenase D and 2 % FBS in RPMI medium) for 1 h at 37 °C with shaking. The 
single cells suspension was then pass through the 40 µm-mesh membrane and 
centrifuged for 10 min at 4 °C. Red blood cells was removed by adding of sterile water 
as described and the cells were washed twice with 1x PBS before plating. 
In vitro stimulation assay and cytokines detection 
Spleen and lymph node cells from the immunized mice were seeded in 24-well tissue 
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culture plate (Nunc) at 2x 105 cells per well in triplicate. The cells were stimulated with 
the respective antigens (10 µg/mL) for 3 days at 37 °C. The medium was harvested and 
centrifuged at 2, 700x g for 10 min at 4 °C. The supernatant was collected and assayed 
for IFN-γ and IL-10 using ELISA kits (Bender MedSystems) according to the 
manufacturer’s protocols. The optical density was measured at 450 nm with correction 
at 570 nm using the Spectra Max 190 microplate reader.  
Statistical analysis 
Statistical significance for the comparison of experimental groups was evaluated using 












B. pseudomallei Hsp70 induces substantial systemic IgG and mucosal IgA response 
in mice after intranasal immunizations. 
To examine whether recombinant Hsp70 could induce Hsp70-specific systemic and 
mucosal antibody response in mice, we immunized the C57/BL6 female mice three 
times intranasally with recombinant Hsp70 or PBS at 14-day intervals. The blood was 
collected at days 28 and 35; nasal wash was collected at day 35. Both the serum and 
nasal wash were assayed for total Hsp70-specific IgG and IgA, respectively. As shown 
in Fig 3-1, Hsp70 induced a strong systemic IgG and mucosal IgA response after 
intranasal immunization as compared to the PBS-immunized group. Total 
Hsp70-specific IgG produced have a low IgG2a/IgG1 ratio (Fig 3-2) indicating a 
Th2-polarized type of response.   
Splenocytes and lymph nodes cells of Hsp70-immunized mice produce IL-10 but not 
IFNγ- upon re-stimulation by Hsp70. 
To investigate the effect of intranasal immunization of Hsp70 on spleen and lymph 
nodes cells, we isolated the spleen and draining cervical lymph nodes from the 
immunized mice and co-cultured the respective cells with recombinant Hsp70. The 
splenocytes and lymph node cells from the mice previously immunized with Hsp70 
 70
produced significant amount of IL-10 upon challenge by Hsp70 in vitro compared to 
the PBS-immunized group in which the level was undetectable (Fig 3-3). In addition, 
there were no detectable IFN-γ in both groups of mice upon challenge with Hsp70 
protein (data not shown).  
M. bovis Hsp65 induces systemic IgG and mucosal IgA response in mice after 
intranasal immunizations. 
In parallel with Burkholderia pseudomallei Hsp70, intranasal immunization of 
recombinant Mycobacterium bovis Hsp65 was found to induce Hsp65-specific systemic 
IgG and mucosal IgA production in mice (Fig 3-4) as well. The total IgG, comparable 
to Hsp70 IgG, has a low ratio of IgG2a/IgG1 (Fig 3-5). 
Splenocytes and lymph nodes cells of Hsp65-immunized mice produce IL-10 but not 
IFN-γ upon re-stimulation with Hsp65. 
To further characterize the effect of intranasal immunization of Hsp65 on spleen cells 
and draining cervical lymph nodes cells, we re-stimulated the respective cells in vitro 
with recombinant Hsp65. Both splenocytes and lymph node cells from the 
Hsp65-immunized group produced significantly higher levels of IL-10 compared to the 
PBS-immunized group (Fig 3-6A). However, we were not able to detect IFN-γ from the 
cultured supernatant of both groups (data not shown). 
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Enhanced IL-10 production in spleenocytes and lymph nodes cells from 
ovalbumin/Hsp70-immunized mice upon re-stimulation with ovalbumin. 
Next, we sought to find out the adjuvant effect of heat shock proteins in intranasal 
immunization of a model antigen, ovalbumin. We divided the C57/BL6 female mice 
into 4 groups, comprising PBS control, ovalbumin, ovalbumin with Hsp70 or 
ovalbumin with Hsp65. The mice were immunized intranasally three times at 14-day 
intervals. The spleen and draining cervical lymph nodes were isolated and re-stimulated 
with ovalbumin. Interestingly, we found that the ovalbumin group co-immunized with 
Hsp70 had enhanced production of IL-10 in comparison to the groups immunized with 
ovalbumin alone or PBS (Fig 3-7). Similar result was obtained for the 
ovalbumin/Hsp65-immunized group, although it was not statistically significant (Fig 
3-8). Again, there was no detectable IFN-γ from the cultured supernatant of both groups 


































Fig 3-1: B. pseudomallei Hsp70 induces substantial systemic IgG and nasal IgA 
production upon intranasal immunization. 
C57/BL6 female mice were divided into two groups, the Hsp70 and the PBS. Intranasal 
immunization was performed thrice in 14-day intervals. Serum samples were collected 
14 days after the second immunization and 7 days after the third immunization and 
assayed for Hsp70-specific IgG. Nasal wash samples were collected 7 days after the 
third immunization and assayed for Hsp70-specific IgA. Results are expressed as mean 





























Fig 3-2: IgG isotyping of serum anti-B. pseudomallei Hsp70 antibody. 
The antibodies produced were predominantly IgG1 with a IgG2a/IgG1 ratio of 0.7 after 
two immunization and 0.67 after three immunization. Results are expressed as mean ± 


















Fig 3-3: Enhanced IL-10 production in lymph nodes cells (A) and splenocytes (B) 
of Hsp70-immunized group upon re-stimulation with Hsp70. 
Lymph node and spleen cells were pooled from four PBS or Hsp70-immunized mice 
and stimulated in vitro with 10 µg/mL Hsp70 in triplicates. Conditioned medium was 
collected after 3 days of incubation and assessed for IL-10 production. Results are 











































Fig 3-4: M. bovis Hsp65 induces systemic IgG and nasal IgA production upon 
intranasal immunization. 
C57/BL6 female mice were divided into two groups, the Hsp65 and the PBS. Intranasal 
immunization was performed thrice in 14-day intervals. Serum samples were collected 
14 days after the second immunization and 7 days after the third immunization and 
assayed for Hsp65-specific IgG. Nasal wash samples were collected 7 days after the 
third immunization and assayed for Hsp65-specific IgA. Results are expressed as mean 





























Fig 3-5: IgG isotyping of serum anti-M. bovis Hsp65 antibody. 
The antibodies produced were predominantly IgG1 with a IgG2a/IgG1 ratio of 0.28 
after two immunization and 0.57 after three immunization. Results are expressed as 
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Fig 3-6: Enhanced IL-10 production in lymph nodes cells (A) and splenocytes (B) 
of Hsp65-immunized group upon re-stimulation with Hsp65. 
Lymph node and spleen cells were pooled from four PBS or Hsp65-immunized mice 
and stimulated in vitro with 10 µg/mL Hsp65 in triplicates. Conditioned medium was 
collected after 3 days of incubation and assessed for IL-10 production. Results are 








































Fig 3-7: Enhanced IL-10 production in lymph nodes cells (A) and splenocytes (B) 
of ovalbumin/Hsp70-immunized group upon re-stimulation with ovalbumin. 
Lymph node and spleen cells were pooled from four PBS, ovalbumin or 
Hsp70/ovalbumin-immunized mice and stimulated in vitro with 10 µg/mL ovalbumin 
in triplicates. Conditioned medium was collected after 3 days of incubation and 




























































Fig 3-8: IL-10 production in lymph nodes cells (A) and splenocytes (B) of 
ovalbumin/Hsp65-immunized group upon re-stimulation with ovalbumin. 
Lymph node and spleen cells were pooled from four PBS, ovalbumin or 
Hsp65/ovalbumin-immunized mice and stimulated in vitro with 10 µg/mL ovalbumin 
in triplicates. Conditioned medium was collected after 3 days of incubation and 






















  In this study, we have demonstrated that B. pseudomallei Hsp70 and M. bovis 
Hsp65 could induce substantial antibody response in mice if immunized intranasally. 
Significant amounts of HSP-specific IgG were detected in the serum even after two 
immunizations. This IgG were predominantly IgG1, which suggests a Th2 type of 
response. HSP-specific mucosal IgA was also detected. This shows that HSPs by 
themselves are immunogenic and are unlike the majority of protein antigens which 
induce tolerance when administered mucosally. This is in agreement with earlier studies 
in which mycobacterial Hsp60 and Hsp70 could be used as carrier molecules that 
conjugate with peptides or oligosaccharides to produce high titers of antibodies without 
initial priming in mice [Barrios et al., 1992; Lussow et al., 1991] 
The splenocytes and lymph node cells isolated from the HSPs-immunized mice 
were shown to secrete IL-10 when co-cultured with the HSPs in vitro. We were not able 
to detect IFN-γ in the co-culture. IL-10 is a pleiotropic cytokine that has diverse 
functions on hemopoietic cells types [Moore et al., 2001]. It plays an important role in 
regulating immune response by suppressing the release of proinflammatory cytokines 
and hence terminating the inflammatory response. Regulatory CD4+ T cell producing 
high amounts of IL10 has been documented and are responsible for the suppression of 
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inflammation [Asseman et al., 1999], induction of tolerance [Han et al., 1996] and 
suppression of airway eosinophilia [Zuany-Amorium et al., 2002]. Our finding suggests 
that HSPs-specific regulatory T cells could be generated upon the intranasal 
immunization. Regulatory T cells are largely subset of CD4+ T cells that exert 
regulatory function through secretion of cytokines like IL-10 and TGF-β or by direct 
cell-cell interaction. The majority of CD4+ regulatory T cells express CD25. Some of 
them are naturally occurring and others are induced specifically upon antigenic 
stimulation [Sakaguchi et al., 2004]. In fact, nasal administration of bacterial Hsp60 
and Hsp70 has been found to induce IL-10-driven regulatory T cells that are effective 
in suppressing arthritis [Prakken et al., 2003; Prakken et al., 2001; Prakken et al., 1997]. 
In summary, intranasal immunization of B. pseudomallei Hsp70 and M. bovis Hsp65 
might have induced a regulatory T cell response, as evidenced by the increase in the 
production of IL-10. In addition, under the microenvironment lacking Th1 polarizing 
signals (indicated by low or undetectable level of IFN-γ), Th2 signals prevail, which 
promote IgG1 isotype switching and further inhibit the development of Th1 responses.  
  Furthermore, we have observed increased production of IL-10 in splenocytes and 
lymph node cells isolated from the mice co-immunized with OVA and HSPs, but not in 
the group immunized with OVA alone, when re-stimulated with OVA in vitro. These 
 82
results indicate that HSPs, once co-administered with an antigen, might govern the 
immune response against that antigen. This adds to the possibility of HSP acting as a 
mucosal adjuvant that may help to prevent inflammation in allergy, arthritis and 
autoimmunity. 
  In the in vitro studies presented in Chapter II, we showed that HSPs are able to 
increase cross-presentation of antigen to antigen-specific CD8 T cells which make IL-2, 
a cytokine that promote T cell proliferation. Nevertheless, the in vivo studies presented 
here showed that HSPs immunization is capable of inducing IL-10, a cytokine that 
could suppress proliferation of T cells. The administration of HSP could be a double 
edge sword, as one hand it enhances presentation to antigen-specific T cells, on the 
other hand, it induces HSP-specific regulatory T cells which could suppress T cell 
proliferation. However, for the induction of HSP-specific regulatory T cells by HSPs to 
dominate over their ability to enhance antigen processing and presentation to 
antigen-specific T cells is likely to depend on the route of administration, the dose of 
co-administered antigen and the duration of immunization. 
  For future studies, we will further investigate the regulatory role of the HSPs by 
identifying the cell types making IL-10 to confirm the presence of the regulatory T cells, 
and perform adoptive transfer of the HSP-reactive, regulatory T cells into the mice of 
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CLONING AND EXPRESSION OF HUMAN HSP72, 
MYCOBACTERIUM BOVIS HSP65, BURKHOLDERIA 











  Recombinant proteins are normally expressed and purified from the E. coli 
system. The contamination of bacterial lipopolysaccharide (LPS) in the protein 
solutions may cause problems for experimental assays, particularly in immunological 
studies. Various methods have been developed to remove the endotoxin from the 
protein solution including extensive washing with buffers containing LPS binder or 
inhibitor like deoxycholate during protein elution; or passing the protein solution 
through a polymyxin B (PMB) column [Petsch et al., 2000]. Nevertheless, these 
methods can only minimize the degree of contamination. Trace amount of the LPS 
present may still interfere with the assays. 
In view of this, we have sought to purify our recombinant proteins from a 
non-bacterial source, the Drosophila Expression System (DES, Invitrogen).  
The DES uses Schneider 2 (S2) cells, a cell line derived from Drosophila melanogaster, 
to produce the recombinant proteins. We plan to clone our HSP genes into a pAc5.1 
constitutive expression vector consisiting the (actin) Ac5 promoter, V5 epitope and 6x 
His-tag. The vector cloned with our HSP genes would then be stably transfected into 
the S2 cells (co-transfected with pCoBlast selection vector) and selected under the 
antibiotic, blasticidin. The protein expressed inside the cells can then be lysed and 
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purified using nickel column affinity purification. 
  In addition to B. pseudomallei Hsp70, Hsp60 and M. bovis Hsp65, we also try to 
purify human Hsp72 from the DES. Human Hsp72 is an inducible form of HSP70 
family and has been reported to play a role in antigen presentation [Wells et al., 1998]. 
It would be interesting to examine its antigen cross presentation activity in comparison 













MATERIALS AND METHODS 
Cloning primers 
Human Hsp72 Primers:  
Sense: 5’ AAAGGTAC/CATGGCCAAAGCC 3’ (KpnI) 
Antisense: 5’ AAGGG/AATTCATCTACCTCCTCA 3’ (EcoRI) 
Mycobacterium bovis Hsp65 Primers: 
Sense: 5’ AACGGTAC/CAAAATGGCCAAGACA 3’ (KpnI) 
Antisense: 5’ GTTG/AATTCGAAATCCATGCCAC 3’ (EcoRI) 
Burkholderia pseudomallei Hsp70 
Sense: 5’ TACGGTAC/CATGGGAAAGATCA 3’ (KpnI) 
Antisense: 5’GCTT/CTAGAGTCCTTCTTCACTTCC 3’ (XbaI) 
Burkholderia pseudomallei Hsp60 
Sense: 5’ ATCGGTAC/CATGGCAGCTAAAG 3’ (KpnI) 
Antisense: 5’ GTTG/AATTCCATGTCCATGCC 3’ (EcoRI) 
DNA templates 
Human Hsp72:  
pcDNA3.1-Hsp72 [G507A (Val to Ile); G1597C (Gly to Ala)] 
Mycobacterium bovis Hsp65: 
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pQE30-Hsp65 
Burkholderia pseudomallei hsp70: 
Genomic DNA from Burkholderia pseudomallei 
Burkholderia pseudomallei Hsp60: 
pQE30-Hsp60 
Polymerase chain reaction (PCR) amplification of heat shock protein genes 
PCR was performed in a total volume of 50 µL reaction mix. The reaction mix 
contained 1x PCR Amplification Buffer, 2 mM of MgCl2, 0.2 mM of dNTPs, 0.4 mM 
of primers, 300 to 500 ng of template DNA, 4 % DMSO (v/v) and 1 unit of BioXact 
DNA Polymerase (Bioline). PCR conditions were as follows: 
Human Hsp72: 
1 cycle of denaturation at 95 °C for 5 min, 
5 cycles of denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min and extension 
at 72 °C for 2 min, 
15 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min and 
extension at 72 °C for 2 min, 
1 cycle of extension at 72 °C for 15 min. 
Mycobacterium bovis Hsp65: 
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1 cycle of denaturation at 94 °C for 5 min, 
20 cycles of denaturation at 94 °C for 1 min, annealing at 60 °C for 1 min and 
extension at 72 °C for 3 min. 
Burkholderia pseudomallei hsp70: 
1 cycle of denaturation at 94 °C for 5 min, 
10 cycles of denaturation at 94 °C for 1 min, annealing at 44 °C for 1 min and 
extension at 72 °C for 2 min, 
15 cycles of denaturation at 94 °C for 1 min, annealing at 60 °C for 1 min and 
extension at 72 °C for 2 min, 
1 cycle of extension at 72 °C for 5 min. 
Burkholderia pseudomallei Hsp60: 
1 cycle of denaturation at 94 °C for 3 min, 
10 cycles of denaturation at 94 °C for 1 min, annealing at 47 °C for 1 min and 
extension at 72 °C for 1 min, 
13 cycles of denaturation at 94 °C for 1 min, annealing at 59 °C for 1 min and 
extension at 72 °C for 1 min. 
DNA gel electrophoresis and extraction 
The amplified DNA fragments were resolved by 1 % agarose gel (containing 0.1 µg/mL 
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of ethidium bromide) electrophoresis in 1 x TBE buffer. The bands of interest were 
excised from the gel and the DNA was extracted using QIAquick Gel Extraction Kit 
(QIAGEN). The extracted DNA was quantitated at OD260 using a spectrophotometer 
(Beckman). 
Cloning of heat shock protein genes into pGEM-T Easy vector  
The extracted DNA was ligated into pGEM-T Easy Vector (Promega) using T4 DNA 
ligase (Promega) at 4 °C overnight. The ligated DNA was transformed into E. coli 
JM109 competent cells by the heat shock method. Briefly, 2 µL of ligation mix was 
added into 50 µL of competent cells and incubated on ice for 20 min. The mixture of 
DNA and competent cells was first heated at 42 °C for 45 s and then rested on ice for 2 
min. 950 µL of LB broth was added into the tube containing cells transformed with 
DNA and incubated at 37 °C for 1.5 h with shaking at 150 rpm. The transformation 
culture was then plated onto a pre-warmed LB agar plate containing 100 µg/mL 
ampicillin (Sigma), 0.5 mM Isopropyl-β-D-thiogalactopyranoside (IPTG) and 80 
µg/mL of X-gal. The positive clones (white colonies) were picked up and inoculated in 
LB broth containing ampicillin at 37 °C overnight. The DNA was purified from the 
bacterial culture using Wizard Plus SV Minipreps DNA Purification System (Promega) 
according to the manufacturer’s protocol. 
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Restriction enzyme digestion analysis and DNA sequencing 
The positive clones were first analyzed by restriction enzyme digestion analysis with 
KpnI, EcoRI (Human Hsp72, M. bovis Hsp65 and B. pseudomallei Hsp60) or XbaI (B. 
pseudomallei Hsp70) (Promega). The clones containing inserts were verified by DNA 
sequencing using the BigDye Terminator Ready Reaction Kit (Applied 
Biosystems-Perkin Elmer) and analyzed by ABI 373A automated DNA sequencer.  
Sequencing primers 
Universal primers: 
T7: 5’ ATACGACTCACTATAGGGCG 3’ 
SP6: 5’ GGTGACACTATAGAA TACTC 3’ 
Human Hsp72 Internal Primers: 
INT-1: 5’ ACCAAGGATGCGGGTGTGAT 3’ 
INT-2: 5’ TGACGTTCAGGATGCCGTTG 3’ 
Mycobacterium bovis Hsp65 Internal Primers: 
INT-1: 5’ TCACCGAGACCCTGCTCAA 3’ 
INT-2: 5’ TGCAGGATATGGCCATTCT 3’ 
Burkholderia pseudomallei Hsp70 Internal Primers: 
INT-1: 5’ GGCCTCGAAGTCAAG 3’ 
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INT-2: 5’ CTCGCCCTGGAACAA 3’ 
Burkholderia pseudomallei Hsp60 Internal Primers: 
INT-1: 5’ GTGCACGACGAACAAG 3’ 
INT-2: 5’ CGATGCCTTCTTCAAC 3’ 
Cloning of heat shock protein genes into pAc5.1A expression vector 
The verified clones in pGEM-T vector were cut either by KpnI/EcoRI (Human Hsp72, 
M. bovis Hsp65 and B. pseudomallei Hsp60) or KpnI/XbaI (B. pseudomallei Hsp70) to 
release the inserts. The inserts were ligated into the pAc5.1A vector (pre-cut with 
KpnI/EcoRI or KpnI/XbaI) using T4 DNA ligase overnight at 4 °C and transformed into 
DH5-α competent cells. The transformation culture was streaked onto the LB agar plate 
containing 100 µg/mL of ampicillin. The resistant clones were rapidly screened using 
PCR. In brief, pinhead quantities of individual clones were inoculated into PCR 
reaction mix containing primers, PCR amplification buffer, MgCl2, dNTPs and Taq 
DNA polymerase (Bioline). The amplified products were analyzed by 0.1 % agarose 
gel electrophoresis in 1x TBE buffer. The clones contained correct sizes of inserts were 
inoculated into 3 mL LB broth with 100 µg/mL ampicillin. The DNA plasmids were 
isolated using Wizard Plus SV Minipreps DNA Purification System. The isolated 
plasmids containing the inserts were re-confirmed by restriction enzyme digestion 
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analysis. 
Transient transfection of pAc5.1A-Hsp constructs into drosophila S2 cells 
The transient transfection of heat shock protein genes into Drosophila Expression 
System (Invitrogen) was done according to manufacturer’s protocol. In brief, 3x 106 S2 
cells was seeded in a 35 mm plate in 3 ml of complete Schneider’s Drosophila medium 
for 16 hours at 28 °C. Transfection mix was prepared by adding of 300 µL of Solution 
A (2M CaCl2 and 19 µg of pAc5.1A-Hsp) to 300 µL of Solution B (2x 
HEPES-buffered saline) and incubated at room temperature for 40 min. The 
transfection mix was then added to the cells and incubated overnight at 28 °C.  
The calcium phosphate solution was removed and cells were washed and re-suspended 
in complete Schneider’s Drosophila medium. The transfected S2 cells were cultured for 
another 4 days before testing for protein expression. 
Stable transfection of pAc5.1A-Hsp constructs into drosophila S2 cells 
The stable transfection of heat shock protein genes into Drosophila Expression System 
was done according to manufacturer’s protocol. In brief, 3x 106 S2 cells was seeded in 
a 35 mm plate in 3 ml complete Schneider’s Drosophila medium for 16 hours at 28 °C. 
Transfection mix was prepared by adding of 300 µL of Solution A (2M CaCl2, 19 µg of 
pAc5.1A-Hsp and 1 µg of pCoBlast) to 300 µL of Solution B (2x HEPES-buffered 
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saline) and incubated at room temperature for 40 min. The transfection steps were as 
described in previous section. After 4 days of culture, the cells were re-suspended in 
complete Schneider’s Drosophila medium containing 25 µg/mL of blasticidin. The 
selective medium was replaced every 4 days until the resistant cells grew out. The 
resistant cells were cultured in 25 cm2 culture flask (Nunc) before testing for protein 
expression. 
Western blot analysis of proteins expression 
The S2 cells harvested from transient and stable transfections were lysed with Cell 
Lysis Buffer (50 mM Tris, 150 mM NaCl, 1 % Triton-X, 1 mM PMSF, 1 µg/mL 
pepstatin, 1 µg/mL leupeptin, pH7.8) on ice for 30 min. The lysate was spun at 14, 000 
rpm at 4 °C for 20 min. The protein content in the supernatant was quantitated using 
Bradford Assay (BioRad). The proteins were resolved on 4 % stacking/ 8 % resolving 
SDS-PAGE and transferred onto nitrocellulose membrane Hybond-C (Amersham 
Pharmacia Biotech) using a semi-dry transfer system for 30 min at 20 V. The membrane 
was first blocked with 5 % non-fat milk TBS-T for 1 h at room temperature and 
incubated with primary antibody (anti-V5 antibody, directed against V5 epitope tagged 
on the recombinant proteins’ C-terminal, 1:5000 dilution, Invitrogen) in the blocking 
buffer for 2 h at room temperature. The membrane was washed 4 times and incubated 
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with secondary antibody (HRP-conjugated goat anti-mouse antibody, 1:5, 000 dilution, 
Sigma) in the blocking buffer for 1 h at room temperature. After 4 washes, the 
conjugated antibody was detected by enhanced chemiluminescence (ECL, Amersham 
Pharmacia Biotech) on autoradiography film (ECL Hyperfilm, Amersham 















Cloning of human Hsp72 into pAc5.1A expression vector  
Human heat shock protein 72 gene (1923 bp) was amplified by PCR from the 
pcDNA3.1-Hsp72 plasmid using the primers Hsp72S and Hsp72AS. The amplified 
gene was cloned into pGEM-T Easy Vector. The positive clones were first checked by 
restriction enzyme digestion (Fig 4-1) and the sequence of the gene was further 
confirmed by DNA sequencing. The sequenced Hsp72 gene was found to have two 
point mutations at G507A (Val to Ile, 507 is the nucleotide position of the Hsp72 gene 
in the NCBI database) and G1597C (Gly to Ala), which are mutations originally 
harbored in the template sequence from the pcDNA3.1 vector. No mutation was 
introduced in the process of our cloning. The Hsp72 gene in the pGEM-T Easy vector 
was then subcloned into the pAc5.1A expression vector (Fig 4-2A, B). The positive 
clones were further confirmed by PCR and restriction enzyme analysis (Fig 4-3). 
Cloning of M. bovis Hsp65 into pAc5.1A expression vector 
M. bovis heat shock protein 65 gene (1623 bp) was amplified by PCR from the 
pQE-30-Hsp65 vector using the primers Hsp65S and Hsp65AS. The amplified gene 
was cloned into the pGEM-T Easy Vector. The positive clones were checked by 
restriction enzyme digestion (Fig 4-4) and the sequence of the gene was confirmed by 
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DNA sequencing. The Hsp65 gene in pGEM-T Easy was then subcloned into the 
pAc5.1A expression vector (Fig 4-5A, B) and positive clones were further confirmed 
by PCR and restriction enzyme analysis (Fig 4-6). To facilitate the study, the 
expression of Hsp65 was continued by other laboratory colleagues. 
Cloning of B. pseudomallei Hsp70 into pAc5.1A expression vector 
B. pseudomallei heat shock protein 70 gene (1953 bp) was amplified by PCR from the 
B. pseudomallei genomic DNA using the primers Hsp70S and Hsp70AS (Fig 4-7). The 
amplified gene was cloned into the pGEM-T Easy Vector. The positive clones were first 
checked by restriction enzyme digestion (Fig 4-8) and further confirmed by DNA 
sequencing. The Hsp70 gene in pGEM-T Easy was then subcloned into the pAc5.1A 
expression vector (Fig 4-9A, B) and the positive clones were confirmed by PCR and 
restriction enzyme analysis (Fig 4-10). 
Cloning of B. pseudomallei Hsp60 into pAc5.1A expression vector 
B. pseudomallei heat shock protein 60 gene (1641 bp) was amplified by PCR from the 
pQE30-Hsp60 using the primers Hsp60S and Hsp60AS (Fig 4-11). The amplified gene 
was cloned into the pGEMT-Easy Vector. Positive clones was first checked by 
restriction enzyme analysis (Fig 4-12) and the sequence of the gene was further 
confirmed by DNA sequencing. The Hsp60 gene in pGEM-T Easy was then subcloned 
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into the pAc5.1A expression vector (Fig 4-13A, B). The positive clones were further 
confirmed by PCR (Fig 4-14) and restriction enzyme analysis.  
Expression of human Hsp72 in drosophila S2 cells 
The pAc5.1A-Hsp72 was transiently and stably transfected into the drosophila S2 cells. 
The expression of Hsp72 protein in the S2 cells was confirmed by western blot analysis 
using anti-V5 antibody (Fig 4-15).  
Expression of B. pseudomallei Hsp70 in drosophila S2 cells 
The pAc5.1A-Hsp70 was transiently and stably transfected into the drosophila S2 cells. 
The expression of Hsp70 protein in the S2 cells was confirmed by western blot analysis 
using anti-V5 antibody (Fig 4-16).  
Transient expression of B. pseudomallei Hsp60 in drosophila S2 cells 
The pAc5.1A-Hsp60 was transiently transfected into the drosophila S2 cells. The 
transient expression of Hsp60 protein in the S2 cells was confirmed by western blot 
analysis using anti-V5 antibody (Fig 4-17). To facilitate the study, the generation of 












Fig 4-1: Restriction enzyme digestion of pGEM-T-Hsp72 (4.9 kb).  
The positive pGEM-T-Hsp72 clone was verified by restriction enzyme digestion using 
kpnI and EcoRI. Two fragments (pGEM-T vector: 3 kb and Hsp72 insert: 1.9 kb) were 






















Fig 4-2A: Schematic representation of pAc5.1A-Hsp72 construct.  
pAc5.1A-Hsp72 was constructed by inserting the human Hsp72 gene into the pAc5.1 
expression vector. KpnI and EcoRI restriction sites were selected for directional cloning. 
The expression vector frame A was selected for in-frame cloning of the gene. The V5 
epitope and 6x-His tag at the C-terminal end facilitated the characterization and 







Human Hsp72 coding sequence
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5’ KpnI site 
 GGT ACC ATG GCC AAA GCC GCG GCA ATC GGC ATC GAC CTG GGC ACC ACC TAC TCC     54 
       M   A   K   A   A   A   I   G   I   D   L   G   T   T   Y   S     16  
   TGC GTG GGG GTG TTC CAA CAC GGC AAG GTG GAG ATC ATC GCC AAC GAC CAG GGC    108 
    C   V   G   V   F   Q   H   G   K   V   E   I   I   A   N   D   Q   G      34  
   AAC CGC ACC ACC CCC AGC TAC GTG GCC TTC ACG GAC ACC GAG CGG CTC ATC GGG    162 
    N   R   T   T   P   S   Y   V   A   F   T   D   T   E   R   L   I   G      52  
   GAT GCG GCC AAG AAC CAG GTG GCG CTG AAC CCG CAG AAC ACC GTG TTT GAC GCG    216 
    D   A   A   K   N   Q   V   A   L   N   P   Q   N   T   V   F   D   A      70  
   AAG CGC CTG ATC GGC CGC AAG TTC GGC GAC CCG GTG GTG CAG TCG GAC ATG AAG    270 
    K   R   L   I   G   R   K   F   G   D   P   V   V   Q   S   D   M   K      88  
   CAC TGG CCT TTC CAG GTG ATC AAC GAC GGA GAC AAG CCC AAG GTG CAG GTG AGC    324 
    H   W   P   F   Q   V   I   N   D   G   D   K   P   K   V   Q   V   S     106  
   TAC AAG GGG GAG ACC AAG GCA TTC TAC CCC GAG GAG ATC TCG TCC ATG GTG CTG    378 
    Y   K   G   E   T   K   A   F   Y   P   E   E   I   S   S   M   V   L     124  
   ACC AAG ATG AAG GAG ATC GCC GAG GCG TAC CTG GGC TAC CCG GTG ACC AAC GCG    432 
    T   K   M   K   E   I   A   E   A   Y   L   G   Y   P   V   T   N   A     142  
   GTG ATC ACC GTG CCG GCC TAC TTC AAC GAC TCG CAG CGC CAG GCC ACC AAG GAT    486 
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    V   I   T   V   P   A   Y   F   N   D   S   Q   R   Q   A   T   K   D     160  
   GCG GGT GTG ATC GCG GGG CTC AAC GTG CTG CGG ATC ATC AAC GAG CCC ACG GCC    540 
    A   G   V   I   A   G   L   N   V   L   R   I   I   N   E   P   T   A     178  
   GCC GCC ATC GCC TAC GGC CTG GAC AGA ACG GGC AAG GGG GAG CGC AAC GTC CTG    594 
    A   A   I   A   Y   G   L   D   R   T   G   K   G   E   R   N   V   L     196  
   ATC TTT GAC CTG GGC GGG GGC ACC TTC GAC GTG TCC ATC CTG ACG ATC GAC GAC    648 
    I   F   D   L   G   G   G   T   F   D   V   S   I   L   T   I   D   D     214  
   GGC ATC TTC GAG GTG AAG GCC ACG GCC GGG GAC ACC CAC CTG GGT GGG GAG GAC    702 
    G   I   F   E   V   K   A   T   A   G   D   T   H   L   G   G   E   D     232  
   TTT GAC AAC AGG CTG GTG AAC CAC TTC GTG GAG GAG TTC AAG AGA AAA CAC AAG    756 
    F   D   N   R   L   V   N   H   F   V   E   E   F   K   R   K   H   K     250  
   AAG GAC ATC AGC CAG AAC AAG CGA GCC GTG AGG CGG CTG CGC ACC GCC TGC GAG    810 
    K   D   I   S   Q   N   K   R   A   V   R   R   L   R   T   A   C   E     268  
   AGG GCC AAG AGG ACC CTG TCG TCC AGC ACC CAG GCC AGC CTG GAG ATC GAC TCC    864 
    R   A   K   R   T   L   S   S   S   T   Q   A   S   L   E   I   D   S     286  
   CTG TTT GAG GGC ATC GAC TTC TAC ACG TCC ATC ACC AGG GCG AGG TTC GAG GAG    918 
    L   F   E   G   I   D   F   Y   T   S   I   T   R   A   R   F   E   E     304  
   CTG TGC TCC GAC CTG TTC CGA AGC ACC CTG GAG CCC GTG GAG AAG GCT CTG CGC    972 
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    L   C   S   D   L   F   R   S   T   L   E   P   V   E   K   A   L   R     322  
   GAC GCC AAG CTG GAC AAG GCC CAG ATT CAC GAC CTG GTC CTG GTC GGG GGC TCC   1026 
    D   A   K   L   D   K   A   Q   I   H   D   L   V   L   V   G   G   S     340  
   ACC CGC ATC CCC AAG GTG CAG AAG CTG CTG CAG GAC TTC TTC AAC GGG CGC GAC   1080 
    T   R   I   P   K   V   Q   K   L   L   Q   D   F   F   N   G   R   D     358  
   CTG AAC AAG AGC ATC AAC CCC GAC GAG GCT GTG GCC TAC GGG GCG GCG GTG CAG   1134 
    L   N   K   S   I   N   P   D   E   A   V   A   Y   G   A   A   V   Q     376  
   GCG GCC ATC CTG ATG GGG GAC AAG TCC GAG AAC GTG CAG GAC CTG CTG CTG CTG   1188 
    A   A   I   L   M   G   D   K   S   E   N   V   Q   D   L   L   L   L     394 
   GAC GTG GCT CCC CTG TCG CTG GGG CTG GAG ACG GCC GGA GGC GTG ATG ACT GCC   1242 
    D   V   A   P   L   S   L   G   L   E   T   A   G   G   V   M   T   A     412  
   CTG ATC AAG CGC AAC TCC ACC ATC CCC ACC AAG CAG ACG CAG ATC TTC ACC ACC   1296 
    L   I   K   R   N   S   T   I   P   T   K   Q   T   Q   I   F   T   T     430  
   TAC TCC GAC AAC CAA CCC GGG GTG CTG ATC CAG GTG TAC GAG GGC GAG AGG GCC   1350 
    Y   S   D   N   Q   P   G   V   L   I   Q   V   Y   E   G   E   R   A     448  
   ATG ACG AAA GAC AAC AAT CTG TTG GGG CGC TTC GAG CTG AGC GGC ATC CCT CCG   1404 
    M   T   K   D   N   N   L   L   G   R   F   E   L   S   G   I   P   P     466  
   GCC CCA GGC GTG CCC CAG ATC GAG GTG ACC TTC GAC ATC GAT GCC AAC GGC ATC   1458 
 104
    A   P   G   V   P   Q   I   E   V   T   F   D   I   D   A   N   G   I     484  
   CTG AAC GTC ACG GCC ACG GAC AAG AGC ACC GGC AAG GCC AAC AAG ATC ACC ATC   1512 
    L   N   V   T   A   T   D   K   S   T   G   K   A   N   K   I   T   I     502 
    ACC AAC GAC AAG GGC CGC CTG AGC AAG GAG GAG ATC GAG CGC ATG GTG CAG GAG   1566 
    T   N   D   K   G   R   L   S   K   E   E   I   E   R   M   V   Q   E     520  
   GCG GAG AAG TAC AAA GCG GAG GAC GAG GTG CAG CGC GAG AGG GTG TCA GCC AAG   1620 
    A   E   K   Y   K   A   E   D   E   V   Q   R   E   R   V   S   A   K     538  
   AAC GCC CTG GAG TCC TAC GCC TTC AAC ATG AAG AGC GCC GTG GAG GAT GAG GGG   1674 
    N   A   L   E   S   Y   A   F   N   M   K   S   A   V   E   D   E   G     556  
   CTC AAG GGC AAG ATC AGC GAG GCC GAC AAG AAG AAG GTG CTG GAC AAG TGT CAA   1728 
    L   K   G   K   I   S   E   A   D   K   K   K   V   L   D   K   C   Q     574  
   GAG GTC ATC TCG TGG CTG GAC GCC AAC ACC TTG GCC GAG AAG GAC GAG TTT GAG   1782 
    E   V   I   S   W   L   D   A   N   T   L   A   E   K   D   E   F   E     592   
   CAC AAG AGG AAG GAG CTG GAG CAG GTG TGT AAC CCC ATC ATC AGC GGA CTG TAC   1836 
    H   K   R   K   E   L   E   Q   V   C   N   P   I   I   S   G   L   Y     610  
   CAG GGT GCC GGT GGT CCC GGG CCT GGG GGC TTC GGG GCT CAG GGT CCC AAG GGA   1890 
    Q   G   A   G   G   P   G   P   G   G   F   G   A   Q   G   P   K   G     628  
      EcoRI site 
 105
   GGG TCT GGG TCA GGC CCC ACC ATT GAG GAG GTA GAT GAA TTC TGC AGA TAT CCA   1944 
    G   S   G   S   G   P   T   I   E   E   V   D   E   F   C   R   Y   P     646   
   GCA CAG TGG CGG CCG CTC GAG TCT AGA GGG CCC TTC GAA GGT AAG CCT ATC CCT   1998 
    A   Q   W   R   P   L   E   S   R   G   P   F   E   G   K   P   I   P     664 
 V5 Epitope     6x-His tag 
   AAC CCT CTC CTC GGT CTC GAT TCT ACG CGT ACC GGT CAT CAT CAC CAT CAC CAT   2052 
    N   P   L   L   G   L   D   S   T   R   T   G   H   H   H   H   H   H     682  
   TGA                                                                       2055 
    *                                                                          
Stop codon  3’ 
Fig 4-2B: Nucleotide sequence analysis of human Hsp72 gene and the 
corresponding amino acid sequence. 
The KpnI-EcoRI fragment contains the full length DNA sequence of human Hsp72 
(1920 bp). The deduced amino acid sequence is shown beneath the corresponding 
nucleotide sequence. The open reading frame (ORF) begins from the ATG at position 7 
and ends with the TGA at position 2055. The original termination codon in the Hsp72 
gene was deleted to facilitate the expression of C-terminal V5 epitope and 6x-His tag.   









Fig 4-3: PCR verification of pAc5.1A-Hsp72 clone. 
The positive pAc5.1A-Hsp72 clone was confirmed by PCR using Hsp72 specific 
primers: Hsp72S and Hsp72AS. A band at 1.9 kb position was detected, which is 



















Fig 4-4: Restriction enzyme analysis of pGEM-T-Hsp65 clone.  
The positive pGEM-T-Hsp65 clone was verified by restriction enzyme digestion using 
kpnI and EcoRI. Two fragments were detected (at 3.0 kb and 1.6 kb position) after the 
digestion, which corresponded to the sizes of pGEM-T vector and Hsp65 insert, 






















Fig 4-5A: Schematic representation of pAc5.1A-Hsp65 construct. 
pAc5.1A-Hsp65 was constructed by inserting the M. bovis Hsp65 gene into the pAc5.1 











M. bovis Hsp65 coding sequence




 5’ KpnI site 
GGT ACC ATG GCC AAG ACA ATT GCG TAC GAC GAA GAG GCC CGT CGC GGC CTC GAG     54 
             M   A   K   T   I   A   Y   D   E   E   A   R   R   G   L   E      16  
   CGG GGC TTG AAC GCC CTC GCC GAT GCG GTA AAG GTG ACA TTG GGC CCC AAG GGC    108 
    R   G   L   N   A   L   A   D   A   V   K   V   T   L   G   P   K   G      34  
   CGC AAC GTC GTC CTG GAA AAG AAG TGG GGT GCC CCC ACG ATC ACC AAC GAT GGT    162 
    R   N   V   V   L   E   K   K   W   G   A   P   T   I   T   N   D   G      54  
   GTG TCC ATC GCC AAG GAG ATC GAG CTG GAG GAT CCG TAC GAG AAG ATC GGC GCC    212 
    V   S   I   A   K   E   I   E   L   E   D   P   Y   E   K   I   G   A      70  
   GAG CTG GTC AAA GAG GTA GCC AAG AAG ACC GAT GAC GTC GCC GGT GAC GGC ACC    270 
    E   L   V   K   E   V   A   K   K   T   D   D   V   A   G   D   G   T      88  
   ACG ACG GCC ACC GTG CTG GCC CAG GCG TTG GTT CGC GAG GGC CTG CGC AAC GTC    324 
    T   T   A   T   V   L   A   Q   A   L   V   R   E   G   L   R   N   V     106  
   GCG GCC GGC GCC AAC CCG CTC GGT CTC AAA CGC GGC ATC GAA AAG GCC GTG GAG    378 
    A   A   G   A   N   P   L   G   L   K   R   G   I   E   K   A   V   E     124  
   AAG GTC ACC GAG ACC CTG CTC AAG GGC GCC AAG GAG GTC GAG ACC AAG GAG CAG    432 
    K   V   T   E   T   L   L   K   G   A   K   E   V   E   T   K   E   Q     142  
   ATT GCG GCC ACC GCA GCG ATT TCG GCG GGT GAC CAG TCC ATC GGT GAC CTG ATC    486 
 110
    I   A   A   T   A   A   I   S   A   G   D   Q   S   I   G   D   L   I     160  
   GCC GAG GCG ATG GAC AAG GTG GGC AAC GAG GGC GTC ATC ACC GTC GAG GAG TCC    540 
    A   E   A   M   D   K   V   G   N   E   G   V   I   T   V   E   E   S     178  
   AAC ACC TTT GGG CTG CAG CTC GAG CTC ACC GAG GGT ATG CGG TTC GAC AAG GGC    594 
    N   T   F   G   L   Q   L   E   L   T   E   G   M   R   F   D   K   G     196  
   TAC ATC TCG GGG TAC TTC GTG ACC GAC CCG GAG CGT CAG GAG GCG GTC CTG GAG    648 
    Y   I   S   G   Y   F   V   T   D   P   E   R   Q   E   A   V   L   E     214  
   GAC CCC TAC ATC CTG CTG GTC AGC TCC AAG GTG TCC ACT GTC AAG GAT CTG CTG    702 
    D   P   Y   I   L   L   V   S   S   K   V   S   T   V   K   D   L   L     232  
   CCG CTG CTC GAG AAG GTC ATC GGA GCC GGT AAG CCG CTG CTG ATC ATC GCC GAG    756 
    P   L   L   E   K   V   I   G   A   G   K   P   L   L   I   I   A   E     250  
   GAC GTC GAG GGC GAG GCG CTG TCC ACC CTG GTC GTC AAC AAG ATC CGC GGC ACC    810 
    D   V   E   G   E   A   L   S   T   L   V   V   N   K   I   R   G   T     268  
   TTC AAG TCG GTG GCG GTC AAG GCT CCC GGC TTC GGC GAC CGC CGC AAG GCG ATG    864 
    F   K   S   V   A   V   K   A   P   G   F   G   D   R   R   K   A   M     286  
   CTG CAG GAT ATG GCC ATT CTC ACC GGT GGT CAG GTG ATC AGC GAA GAG GTC GGC    918 
    L   Q   D   M   A   I   L   T   G   G   Q   V   I   S   E   E   V   G     304  
   CTG ACG CTG GAG AAC GCC GAC CTG TCG CTG CTA GGC AAG GCC CGC AAG GTC GTG    972 
 111
    L   T   L   E   N   A   D   L   S   L   L   G   K   A   R   K   V   V     322  
   GTC ACC AAG GAC GAG ACC ACC ATC GTC GAG GGC GCC GGT GAC ACC GAC GCC ATC   1026 
    V   T   K   D   E   T   T   I   V   E   G   A   G   D   T   D   A   I     340  
   GCC GGA CGA GTG GCC CAG ATC CGC CAG GAG ATC GAG AAC AGC GAC TCC GAC TAC   1080 
    A   G   R   V   A   Q   I   R   Q   E   I   E   N   S   D   S   D   Y     358  
   GAC CGT GAG AAG CTG CAG GAG CGG CTG GCC AAG CTG GCC GGT GGT GTC GCG GTG   1134 
    D   R   E   K   L   Q   E   R   L   A   K   L   A   G   G   V   A   V     376  
   ATC AAG GCC GGT GCC GCC ACC GAG GTC GAA CTC AAG GAG CGC AAG CAC CGC ATC   1188 
    I   K   A   G   A   A   T   E   V   E   L   K   E   R   K   H   R   I     394  
   GAG GAT GCG GTT CGC AAT GCC AAG GCC GCC GTC GAG GAG GGC ATC GTC GCC GGT   1242 
    E   D   A   V   R   N   A   K   A   A   V   E   E   G   I   V   A   G     412  
   GGG GGT GTG ACG CTG TTG CAA GCG GCC CCG ACC CTG GAC GAG CTG AAG CTC GAA   1296 
    G   G   V   T   L   L   Q   A   A   P   T   L   D   E   L   K   L   E     430  
   GGC GAC GAG GCG ACC GGC GCC AAC ATC GTG AAG GTG GCG CTG GAG GCC CCG CTG   1350 
    G   D   E   A   T   G   A   N   I   V   K   V   A   L   E   A   P   L     448  
   AAG CAG ATC GCC TTC AAC TCC GGG CTG GAG CCG GGC GTG GTG GCC GAG AAG GTG   1404 
    K   Q   I   A   F   N   S   G   L   E   P   G   V   V   A   E   K   V     466  
   CGC AAC CTG CCG GCT GGC CAC GGA CTG AAC GCT CAG ACC GGT GTC TAC GAG GAT   1458 
 112
    R   N   L   P   A   G   H   G   L   N   A   Q   T   G   V   Y   E   D     484  
   CTG CTC GCT GCC GGC GTT GCT GAC CCG GTC AAG GTG ACC CGT TCG GCG CTG CAG   1512 
    L   L   A   A   G   V   A   D   P   V   K   V   T   R   S   A   L   Q     502  
   AAT GCG GCG TCC ATC GCG GGG CTG TTC CTG ACC ACC GAG GCC GTC GTT GCC GAC   1566 
    N   A   A   S   I   A   G   L   F   L   T   T   E   A   V   V   A   D     520  
   AAG CCG GAA AAG GAG AAG GCT TCC GTT CCC GGT GGC GGC GAC ATG GGT GGC ATG   1620 
    K   P   E   K   E   K   A   S   V   P   G   G   G   D   M   G   G   M     538  
 EcoRI site 
   GAT TTC GAA TTC TGC AGA TAT CCA GCA CAG TGG CGG CCG CTC GAG TCT AGA GGG   1674 
    D   F   E   F   C   R   Y   P   A   Q   W   R   P   L   E   S   R   G     556  
   V5 Epitope 
   CCC TTC GAA GGT AAG CCT ATC CCT AAC CCT CTC CTC GGT CTC GAT TCT ACG CGT   1728 
    P   F   E   G   K   P   I   P   N   P   L   L   G   L   D   S   T   R     574  
  6x-His tag  
   ACC GGT CAT CAT CAC CAT CAC CAT TGA                                       1755 
    T   G   H   H   H   H   H   H   *                                         582 
    Stop codon        3’ 
   
 113
Fig 4-5B: Nucleotide sequence analysis of M. bovis Hsp65 gene and the 
corresponding amino acid sequence. 
The KpnI-EcoRI fragment contains the full length DNA sequence of M. bovis Hsp65 
(1620 bp). The deduced amino acid sequence is shown beneath the corresponding 
nucleotide sequence. The open reading frame (ORF) begins from the ATG at position 7 
and ends with the TGA at position 1755. The original termination codon in the Hsp65 



















Fig 4-6: Restriction enzymes analysis of pAc5.1A-Hsp65 clone. 
The positive pAc5.1A-Hsp65 clone was verified by restriction enzyme digestion using 




















Fig 4-7: PCR amplification of full-length B. pseudomallei Hsp70 gene (1.95 kb).  
B. pseudomallei Hsp70 gene was amplified from the genomic DNA using cloning 




















Fig 4-8: Restriction enzyme analysis of pGEM-T-Hsp70 clone. 
The positive pGEM-T-Hsp70 clone was confirmed by restriction enzyme digestion 






















Fig 4-9A: Schematic representation of pAc5.1A-Hsp70 construct. 
pAc5.1A-Hsp70 was constructed by inserting the B. pseudomallei Hsp70 gene into the 
pAc5.1 expression vector. KpnI and XbaI restriction sites were selected for directional 











Translational Termination (stop codon)




5’ KpnI site 
GGT ACC ATG GGA AAG ATC ATC GGT ATT GAC CTC GGC ACC ACG AAC TCG TGC GTC     54 
             M   G   K   I   I   G   I   D   L   G   T   T   N   S   C   V      16  
   GCG ATC ATG GAA GGC AAC CAG GTC AAG GTC ATC GAG AAT TCG GAA GGC GCG CGC    108 
    A   I   M   E   G   N   Q   V   K   V   I   E   N   S   E   G   A   R      34  
   ACG ACG CCG TCG ATC ATC GCG TAC ATG GAC GAC AAC GAA GTG CTC GTC GGC GCG    162 
    T   T   P   S   I   I   A   Y   M   D   D   N   E   V   L   V   G   A      52  
   CCC GCC AAG CGC CAA TCG GTG ACG AAC CCG AAG AAC ACG CTG TTC GCG GTC AAG    216 
    P   A   K   R   Q   S   V   T   N   P   K   N   T   L   F   A   V   K      70  
   CGC CTG ATC GGC CGC CGT TTC GAA GAG AAG GAA GTC CAG AAG GAC ATC GGC CTG    270 
    R   L   I   G   R   R   F   E   E   K   E   V   Q   K   D   I   G   L      88  
   ATG CCG TAC GCG ATC ATC AAG GCG GAC AAC GGC GAC GCG TGG GTC GAG GCG CAC    324 
    M   P   Y   A   I   I   K   A   D   N   G   D   A   W   V   E   A   H     106  
   GGC GAG AAG CTC GCG CCG CCG CAG GTG TCG GCC GAA GTG CTG CGC AAG ATG AAG    378 
    G   E   K   L   A   P   P   Q   V   S   A   E   V   L   R   K   M   K     124  
   AAG ACG GCC GAA GAC TAC CTC GGC GAG CCG GTC ACG GAA GCC GTG ATC ACG GTG    432 
    K   T   A   E   D   Y   L   G   E   P   V   T   E   A   V   I   T   V     142  
   CCG GCG TAC TTC AAC GAC AGC CAG CGC CAG GCG ACG AAG GAC GCG GGG CGC ATC    486 
 119
    P   A   Y   F   N   D   S   Q   R   Q   A   T   K   D   A   G   R   I     160  
   GCG GGC CTC GAA GTC AAG CGG ATC ATC AAC GAG CCG ACC GCG GCC GCG CTC GCG    540 
    A   G   L   E   V   K   R   I   I   N   E   P   T   A   A   A   L   A     178  
   TTC GGC CTC GAC AAG GCC GAG AAG GGC GAT CGC AAG ATC GCG GTG TAT GAC CTC    594 
    F   G   L   D   K   A   E   K   G   D   R   K   I   A   V   Y   D   L     196  
   GGC GGC GGC ACG TTC GAC GTG TCG ATC ATC GAG ATC GCG GAC GTC GAC GGC GAA    648 
    G   G   G   T   F   D   V   S   I   I   E   I   A   D   V   D   G   E     214  
   ATG CAG TTC GAA GTG CTG TCG ACC AAC GGC GAC ACG TTC CTC GGC GGC GAG GAC    702 
    M   Q   F   E   V   L   S   T   N   G   D   T   F   L   G   G   E   D     232  
   TTC GAT CAG CGC ATC ATC GAT TAC ATC ATC GGC GAA TTC AAG AAG GAG CAG GGC    756 
    F   D   Q   R   I   I   D   Y   I   I   G   E   F   K   K   E   Q   G     250  
   GTC GAT CTC TCG AAG GAC GTG CTC GCG CTG CAG CGC CTG AAG GAA GCG GCC GAG    810 
    V   D   L   S   K   D   V   L   A   L   Q   R   L   K   E   A   A   E     268  
   AAG GCG AAG ATC GAG CTG TCG TCG AGC CAG CAG ACC GAA ATC AAC CTG CCG TAC    864 
    K   A   K   I   E   L   S   S   S   Q   Q   T   E   I   N   L   P   Y     286  
   ATC ACG GCC GAC GCG TCG GGC CCG AAG CAC TTG AAC CTG AAG GTC ACG CGC GCG    918 
    I   T   A   D   A   S   G   P   K   H   L   N   L   K   V   T   R   A     304  
   AAG CTC GAG GCG CTC GTC GAG GAT CTG GTC GAG CGC ACG ATC GAG CCG TGC CGC    972 
 120
    K   L   E   A   L   V   E   D   L   V   E   R   T   I   E   P   C   R     322  
   ACC GCG ATC AAG GAC GCG GGC GTC AAG GTG TCG GAC ATC GAC GAC GTG ATC CTC   1026 
    T   A   I   K   D   A   G   V   K   V   S   D   I   D   D   V   I   L     340  
   GTC GGC GGC CAG ACC CGC ATG CCG AAG GTG CAG GAG AAG GTG AAG GAA TTC TTC   1080 
    V   G   G   Q   T   R   M   P   K   V   Q   E   K   V   K   E   F   F     358  
   GGC AAG GAG CCG CGC CGC GAC GTG AAC CCG GAC GAA GCC GTC GCG GTG GGC GCG   1134 
    G   K   E   P   R   R   D   V   N   P   D   E   A   V   A   V   G   A     376  
   GCG ATC CAG GGC CAG GTG CTT TCG GGC GAC CGC AAG GAC GTG CTG CTG CTC GAC   1188 
    A   I   Q   G   Q   V   L   S   G   D   R   K   D   V   L   L   L   D     394  
   GTG ACG CCG CTG TCG CTC GGC ATC GAG ACG CTC GGC GGC GTG ATG ACG AAG ATG   1242 
    V   T   P   L   S   L   G   I   E   T   L   G   G   V   M   T   K   M     412  
   ATC AAC AAG AAC ACG ACG ATC CCG ACG AAG CAC GCT CAG GTG TAT TCG ACG GCG   1296 
    I   N   K   N   T   T   I   P   T   K   H   A   Q   V   Y   S   T   A     430  
   GAC GAC AAC CAG GGC GCC GTG ACG ATC AAG GTG TTC CAG GGC GAG CGC GAG ATG   1350 
    D   D   N   Q   G   A   V   T   I   K   V   F   Q   G   E   R   E   M     448  
   GCG GCG GGC AAC AAG CTG CTC GGC GAG TTC AAC CTC GAG GGC ATC CCG CCC GCG   1404 
    A   A   G   N   K   L   L   G   E   F   N   L   E   G   I   P   P   A     466  
   CCG CGC GGC GTG CCG CAG ATC GAA GTG ACC TTC GAC ATC GAC GCG AAC GGC ATC   1458 
 121
    P   R   G   V   P   Q   I   E   V   T   F   D   I   D   A   N   G   I     484  
   CTG CAC GTC GGC GCG AAG GAC AAG GCG ACC GGC AAG GAA AAC AAG ATC ACG ATC   1512 
    L   H   V   G   A   K   D   K   A   T   G   K   E   N   K   I   T   I     502  
   AAG GCG AAC TCG GGC CTG TCC GAA GCC GAG ATC GAG AAG ATG GTG AAG GAC GCG   1566 
    K   A   N   S   G   L   S   E   A   E   I   E   K   M   V   K   D   A     520  
   GAA GCG AAC GCG GCG GAA GAC CAC AAG CTG CGT GAG CTC GCC GAA TCC CGC AAC   1620 
    E   A   N   A   A   E   D   H   K   L   R   E   L   A   E   S   R   N     538  
   CAG GGC GAT GCG CTC GTG CAC AGC ACG AAG AAG GCG CTC ACC GAG TAC GGC GAC   1674 
    Q   G   D   A   L   V   H   S   T   K   K   A   L   T   E   Y   G   D     556  
   AAG CTG GAG GCG GGC GAG AAG GAG AAG ATC GAA GCG GCG CTC AAG GAG CTC GAG   1728 
    K   L   E   A   G   E   K   E   K   I   E   A   A   L   K   E   L   E     574  
   GAC GTG CTG AAG AAC GCG TCG AGC GAC AAG GCG GCG ATC GAC GCG AAG GTC GAA   1782 
    D   V   L   K   N   A   S   S   D   K   A   A   I   D   A   K   V   E     592  
   GCG GTT GCG ACG GCG TCG CAG AAG CTC GGC GAG AAG ATG TAC GCC GAC ATG CAG   1836 
    A   V   A   T   A   S   Q   K   L   G   E   K   M   Y   A   D   M   Q     610  
   GCG CAG CAG GCA GGC GCC GCG GGC GCG GCC GGG GCG GCA GCC GAA GGT GCG TCG   1890 
    A   Q   Q   A   G   A   A   G   A   A   G   A   A   A   E   G   A   S     628  
   GCG CAG GGC GGC GCG CAG CCG GCC GAC GAC GTC GTC GAC GCC GAC TTC AAG GAA   1944 
 122
    A   Q   G   G   A   Q   P   A   D   D   V   V   D   A   D   F   K   E     646  
  XbaI site   V5 Epitope 
   GTG AAG AAG GAC TCT AGA GGG CCC TTC GAA GGT AAG CCT ATC CCT AAC CCT CTC   1998 
    V   K   K   D   S   R   G   P   F   E   G   K   P   I   P   N   P   L     664  
     6x-His tag     
   CTC GGT CTC GAT TCT ACG CGT ACC GGT CAT CAT CAC CAT CAC CAT TGA           2046 
    L   G   L   D   S   T   R   T   G   H   H   H   H   H   H   *             679 
       Stop codon     3’ 
 
Fig 4-9B: Nucleotide sequence analysis of B. pseudomallei Hsp70 gene and the 
corresponding amino acid sequence. 
The KpnI-XbaI fragment contains the full length DNA sequence of B. pseudomallei 
Hsp70 (1950 bp). The deduced amino acid sequence is shown beneath the 
corresponding nucleotide sequence. The open reading frame (ORF) begins from the 
ATG at position 7 and ends with the TGA at position 2046. The original termination 
codon in the Hsp70 gene was deleted to facilitate the expression of C-terminal V5 











Fig 4-10: PCR verification of pAc5.1A-Hsp70 clone. 
The positive pAc5.1A-Hsp70 clone was validated by PCR using Hsp70-specific 
primers Hsp70S and Hsp70AS. A band at 2 kb was detected, which corresponded to the 



















Fig 4-11: PCR amplification of full-length B. pseudomallei Hsp60 gene. 
B. pseudomallei Hsp60 gene was amplified from the pQE30-Hsp60 using cloning 





















Fig 4-12: Restriction enzyme analysis of pGEM-T-Hsp60 clone. The positive 
pGEM-T-Hsp60 clone was verified by RE digestion using KpnI and EcoRI. M: 1 kb 

























Fig 4-13A: Schematic representation of pAc5.1A-Hsp60 construct. 
pAc5.1A-Hsp60 was constructed by inserting the B. pseudomallei Hsp60 gene into the 











Translational Termination (stop codon)




5’ KpnI site 
GGT ACC ATG GCA GCT AAA GAC GTC GTA TTC GGC GAT TCC GCA CGC GCG AAG ATG     54 
             M   A   A   K   D   V   V   F   G   D   S   A   R   A   K   M      16  
   GTC GAA GGC GTG AAC ATT CTC GCC AAC GCT GTG AAG GTC ACG CTG GGT CCG AAG    108 
    V   E   G   V   N   I   L   A   N   A   V   K   V   T   L   G   P   K      34  
   GGC CGC AAC GTG GTG CTC GAG CGC AGC TTC GGC GGC CCG ACG GTC ACG AAG GAC    162 
    G   R   N   V   V   L   E   R   S   F   G   G   P   T   V   T   K   D      52  
   GGT GTG TCG GTC GCG AAG GAA ATC GAG CTG AAG GAC AAG CTC CAG AAC ATG GGC    216 
    G   V   S   V   A   K   E   I   E   L   K   D   K   L   Q   N   M   G      70  
   GCG CAG ATG GTC AAG GAA GTC GCT TCC AAG ACC AGC GAC AAC GCC GGC GAC GGC    270 
    A   Q   M   V   K   E   V   A   S   K   T   S   D   N   A   G   D   G      88  
   ACG ACG ACG GCC ACC GTC CTC GCG CAA TCG ATC GTC CGC GAA GGC ATG AAG TAC    324 
    T   T   T   A   T   V   L   A   Q   S   I   V   R   E   G   M   K   Y     106  
   GTC GCA TCG GGC ATG AAC CCG ATG GAC CTG AAG CGC GGC ATC GAC AAG GCA GTC    378 
    V   A   S   G   M   N   P   M   D   L   K   R   G   I   D   K   A   V     124  
   GCC GCG GCA GTC GAA GAG CTG AAG AAG ATC AGC AAG CCG TGC ACG ACG AAC AAG    432 
    A   A   A   V   E   E   L   K   K   I   S   K   P   C   T   T   N   K     142  
   GAA ATC GCG CAA GTC GGC GCG ATC TCG GCG AAC AGC GAT TCG TCG ATC GGC GAT    486 
 128
    E   I   A   Q   V   G   A   I   S   A   N   S   D   S   S   I   G   D     160  
   CGC ATC GCT GAA GCG ATG GAC AAG GTC GGC AAG GAA GGC GTG ATC ACC GTC GAA    540 
    R   I   A   E   A   M   D   K   V   G   K   E   G   V   I   T   V   E     178  
   GAC GGC AAG TCG CTC GCC GAC GAG CTC GAC GTC GTC GAA GGC ATG CAG TTC GAC    594 
    D   G   K   S   L   A   D   E   L   D   V   V   E   G   M   Q   F   D     196  
   CGC GGC TAC CTG TCG CCG TAC TTC ATC AAC AAC CCG GAC AAG CAA GTC GCC GTC    648 
    R   G   Y   L   S   P   Y   F   I   N   N   P   D   K   Q   V   A   V     214  
   CTC GAG AAC CCG TTC GTG CTG CTG CAC GAC AAG AAG GTG TCG AAC ATC CGC GAC    702 
    L   E   N   P   F   V   L   L   H   D   K   K   V   S   N   I   R   D     232  
   CTG CTG CCG GTG CTC GAG CAA GTC GCG AAG GCT GGC CGT CCG CTG CTG ATC ATC    756 
    L   L   P   V   L   E   Q   V   A   K   A   G   R   P   L   L   I   I     250  
   GCC GAA GAC GTC GAA GGC GAA GCG CTC GCA ACG CTG GTC GTC AAC AAC ATC CGC    810 
    A   E   D   V   E   G   E   A   L   A   T   L   V   V   N   N   I   R     268  
   GGC ATC CTG AAG ACC GTT GCG GTC AAG GCA CCG GGC TTC GGC GAT CGT CGC AAG    864 
    G   I   L   K   T   V   A   V   K   A   P   G   F   G   D   R   R   K     286  
   GCG ATG CTG GAA GAC ATC GCG ATC CTG ACG GGC GGC CAG GTC ATC GCG GAA GAA    918 
    A   M   L   E   D   I   A   I   L   T   G   G   Q   V   I   A   E   E     304  
   ACC GGC CTC ACG CTC GAG AAG GCA ACG CTG GCA GAA CTG GGC CAG GCG AAG CGC    972 
 129
    T   G   L   T   L   E   K   A   T   L   A   E   L   G   Q   A   K   R     322  
   ATC GAA GTG GGC AAG GAA AAC ACG ACG ATC ATC GAC GGC GCG GGC GAA GCC GTG   1026 
    I   E   V   G   K   E   N   T   T   I   I   D   G   A   G   E   A   V     340  
   AAC ATC GAA GCG CGC GTC AAG CAA ATC CGC ACG CAA ATC GAA GAA GCG ACG TCG   1080 
    N   I   E   A   R   V   K   Q   I   R   T   Q   I   E   E   A   T   S     358  
   GAC TAC GAC CGT GAA AAG CTG CAA GAG CGC GTG GCC AAG CTG GCA GGC GGC GTG   1134 
    D   Y   D   R   E   K   L   Q   E   R   V   A   K   L   A   G   G   V     376  
   GCG GTG ATC AAG GTC GGC GCT GCG ACC GAA GTC GAA ATG AAG GAA AAG AAG GCA   1188 
    A   V   I   K   V   G   A   A   T   E   V   E   M   K   E   K   K   A     394  
   CGT GTC GAG GAC GCG CTG CAC GCC ACC CGC GCT GCC GTT GAA GAA GGC ATC GTC   1242 
    R   V   E   D   A   L   H   A   T   R   A   A   V   E   E   G   I   V     412  
   CCG GGC GGC GGC GTC GCG CTG ATC CGC GCA CGC ACC GCG ATC GCG AGC CTG ACC   1296 
    P   G   G   G   V   A   L   I   R   A   R   T   A   I   A   S   L   T     430  
   GGC GTG AAC GCC GAC CAG AAC GCC GGC ATC AAG ATC GTG CTG CGC GCG ATG GAA   1350 
    G   V   N   A   D   Q   N   A   G   I   K   I   V   L   R   A   M   E     448  
   GAG CCG CTG CGC CAG ATC GTC ACG AAC GGC GGC GAA GAA GCG AGC GTC GTG GTG   1404 
    E   P   L   R   Q   I   V   T   N   G   G   E   E   A   S   V   V   V     466  
   GCG GCA GTT GCT GCG GGC AAG GGC AAC TAC GGC TAC AAC GCG GCG ACG GGC GAG   1458 
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    A   A   V   A   A   G   K   G   N   Y   G   Y   N   A   A   T   G   E     484  
   TAC GTC GAC ATG GTC GAA GCC GGC GTC GTC GAT CCG ACG AAG GTC ACC CGT ACC   1512 
    Y   V   D   M   V   E   A   G   V   V   D   P   T   K   V   T   R   T     502  
   GCG CTG CAG AAC GCG GCT TCG GTC GCC GGC CTG CTG CTG ACG ACG GAC GCA GCC   1566 
    A   L   Q   N   A   A   S   V   A   G   L   L   L   T   T   D   A   A     520  
   GTT GCC GAA CTG CCG AAG GAA GAC GCT CCG ATG CCG GGC GGC ATG CCG GGC GGC   1620 
    V   A   E   L   P   K   E   D   A   P   M   P   G   G   M   P   G   G     538  
    EcoRI site 
   ATG GGC GGC ATG GGC ATG GAC ATG GAA TTC TGC AGA TAT CCA GCA CAG TGG CGG   1674 
    M   G   G   M   G   M   D   M   E   F   C   R   Y   P   A   Q   W   R     556  
     V5 Epitope 
   CCG CTC GAG TCT AGA GGG CCC TTC GAA GGT AAG CCT ATC CCT AAC CCT CTC CTC   1728 
    P   L   E   S   R   G   P   F   E   G   K   P   I   P   N   P   L   L     574 
     6x-His tag 
   GGT CTC GAT TCT ACG CGT ACC GGT CAT CAT CAC CAT CAC CAT TGA               1773 
    G   L   D   S   T   R   T   G   H   H   H   H   H   H   *                 588 
       Stop codon       3’ 
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Fig 4-13B: Nucleotide sequence analysis of B. pseudomallei Hsp60 gene and the 
corresponding amino acid sequence. 
The KpnI-EcoRI fragment contains the full length DNA sequence of B. pseudomallei 
Hsp60 (1638 bp). The deduced amino acid sequence is shown beneath the 
corresponding nucleotide sequence. The open reading frame (ORF) begins from the 
ATG at position 7 and ends with the TGA at position 1773. The original termination 
codon in the Hsp60 gene was deleted to facilitate the expression of C-terminal V5 


















Fig 4-14: PCR verification of pAc5.1A-Hsp60 clone. 
The positive pAc5.1A-Hsp60 clone was verified by PCR using the Hsp60-specific 
primers Hsp60S and Hsp60AS. M: 1 kb DNA marker; Lane 1-5: positive clones of 






































Fig 4-15: Expression of human Hsp72 recombinant protein (75.7 kDa) in S2 cells.  
A. Western Blot analysis of S2 cells transiently transfected with pAc5.1A-Hsp72 
construct. The transfected cells were harvested and lysed after 5 days of transfection. B. 
Western Blot analysis of S2 cells stably transfected with pAc5.1A-Hsp72 construct. 
The transfected cells were harvested and lysed after 3 weeks of blasticidin selection. 
Anti-V5 antibody was used for recombinant protein detection. For Figure A, Mock: 5 
days after mock transfection without the expression vector; Hsp72 5dT: 5 days after 
transient transfection with pAc5.1A-Hsp72 construct. For Figure B, Mock: stable 
transfection with only the pCoBlast vector; Hsp72S: stable transfection with both 

































Fig 4-16: Expression of B. pseudomallei Hsp70 recombinant protein (75.4 kDa) in 
S2 cells.  
A. Western Blot analysis of S2 cells transiently transfected with pAc5.1A-Hsp70 
construct. The transfected cells were harvested and lysed after 5 days of transfection. B. 
Western Blot analysis of S2 cells stably transfected with pAc5.1A-Hsp70 construct. 
The transfected cells were harvested and lysed after 3 weeks of blasticidin selection. 
Anti-V5 antibody was used for recombinant protein detection. For Figure A, Mock: 5 
days after mock transfection without the expression vector; Hsp70 5dT: 5 days after 
transient transfection with pAc5.1A-Hsp70 construct. For Figure B, Mock: stable 
transfection with only the pCoBlast vector; Hsp70S: stable transfection with both 

















Fig 4-17: Expression of B. pseudomallei Hsp60 recombinant protein (65.3 kDa) in 
S2 cells.  
Western Blot analysis of S2 cells transiently transfected with pAc5.1A-Hsp60 construct. 
The transfected cells were harvested and lysed after 5 days of transfection. Anti-V5 
antibody was used for recombinant protein detection. Degradation products of the 
recombinant Hsp60 protein were also detected (indicated by ←). Mock: 5 days after 
mock transfection without the expression vector; Hsp60 5dT: 5 days after transient 








  We reported here the successful cloning and expression of human Hsp72, B. 
pseudomallei Hsp70 and Hsp60 in the Drosophila Expression System (DES). We have 
also completed the cloning of M. bovis Hsp65 and the expression was verified by 
another laboratory member. For future work, purification conditions for the optimal 
yield of the recombinant proteins will be assessed.  
  With these endotoxin-free recombinant HSPs, we will be able to clarify the 
signaling enigma caused by LPS-contaminated HSPs. These LPS-free HSPs can be 
used to stimulate dendritic cells and we can identify the cellular components which 
contribute to enhanced cross presentation of antigen in DCs to T cells by HSPs using a 
two-dimensional gel electrophoresis (2D-GE) approach. This could potentially identify 
the mechanism of HSPs in enhancing cross-presentation, either through the activation 
of DCs and/or the upregulation of the antigen processing/presentation machinery. 
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SUMMARY AND CONCLUSIONS 
Heat shock proteins (HSPs) are evolutionary conserved proteins that play 
essential roles in protein folding, trafficking and degradation. Recently, their 
immunological roles in enhancement of antigen cross presentation, direct activation of 
dendritic cells and regulation of autoimmunity have been reported and reviewed.  
In our present studies, we sought to understand the immunomodulatory roles of 
Burkholderia pseudomallei Hsp70, Hsp60 and Mycobacterium bovis Hsp65 collectively. 
From the in vitro antigen presentation studies, we found that these HSPs could promote 
cross-presentation of exogenous ovalbumin whole protein on the dendritic cells, DC2.4 
to a T cell hybridoma, B3Z and hence activate the naïve T cells to secrete IL-2. This 
process was found to be independent of LPS contamination and CD54 expression. In 
addition, results from the peptide pulsing experiments seem to suggest that the effect of 
HSPs on enhancement of cross-presentation involves the initial steps of processing 
before the short 18-residue peptides were generated. Validation would require the use 
of lower concentration of peptides. In the investigation of direct signaling effect of 
HSPs, our data strongly suggest that LPS contamination in the HSP preparations have 
been contributing to the release of TNF-α and activation of NF-κB in DC.  
In a mouse model of intranasal immunization, we are able to detect 
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HSP-specific IgG and IgA in the serum and nasal wash, respectively in the mice after 
two or three times of HSP intranasal immunization. These data support that HSPs by 
themselves are immunogenic. Surprisingly, HSP-immunization is also shown to induce 
regulatory cells secreting IL-10. We surmise that HSPs are capable of generating two 
separate immune reactions, where on one hand they could enhance antigen 
cross-presentation and are immunogenic, on the other hand they might initiate 
regulatory response by inducing IL-10 secreting cells. The fine-tuning of the two 
reactions could be dependent on the various parameters during the immunization, 
particularly the route of immunization. 
  Finally, we report the successful cloning and expression of human Hsp72, B. 
pseudomallei Hsp70 and Hsp60 in the endotoxin-free Drosophila Expression System 
(DES) that allows us to further investigate the signaling pathway involved in antigen 
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